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Primary hepatocytes of adult human and rodent origin are essential components for 
developing drugs against infectious pathogens and for studying drug mediated liver 
toxicity. One of the key drawbacks limiting the use of these primary hepatocytes in 
vitro is their rapid loss of differentiated function, polarity, inability to recapitulate 
drug responses accurately and failure to capture the life cycle of pathogens.   
Although multiple platforms have been developed to improve functional maintenance 
of hepatocytes in culture, there is little understanding on the utility of these models for 
applications like toxicology and infections by various liver specific pathogens. In this 
thesis we have studied the utility of spheroid cultures of human hepatocytes to support 
hepatitis C infection and replication and sandwich culture of rat hepatocytes and co-
culture of rat hepatocytes with fibroblasts for drug testing applications. 
Spheroid culture models of human hepatocytes and human hepatoma cells maintain 
and enhance liver specific functions, while localizing various liver specific proteins at 
domains similar to that found in vivo. These spheroid models maintain polarity over 
prolonged cultures and support glycoprotein mediated HCV entry. Huh 7.5 also 
support higher levels of replication of HCV virus in vitro. This makes it a suitable 
model to screen for drugs inhibiting HCV entry and replication.  
Rat hepatocyte culture with fibroblasts (co-culture) enhances hepatocyte specific 
synthetic and metabolic functions. However co-culture of hepatocytes with fibroblasts 
inhibits drug-induced CYP 450 responses. We found that TGFβ1 is an important 
cytokine in co-culture responsible for repression of drug-induced responses.   Soluble 
factor mediated repression of drug-induced CYP 450 responses makes co-culture an 
unsuitable model to study drug induction/inhibition and drug-drug interactions.   
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We have analyzed the strengths of different hepatocyte culture models and 
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1.1 Drug development process: 
Development of a new drug and its launch into the market costs over a billion dollars 
over a period of 12 years, which makes it a very time consuming and expensive 
process [1].  
 
 
Figure 1: Schematic of drug discovery process (Adapted from 
www.gsdpharmaconsulting.com). 
The discovery phase starts with identification of the best targets specific to a disease. 
Identification of drug targets allows for chemists and biologists to perform targeted 
drug discovery by high throughput screening of existing chemical or biological 
libraries or de novo structure based design [2].  As seen from the above schematic 
there is a huge attrition in the number of compounds from early phases of drug 
discovery to compounds entering clinical trials. It is less than 0.1% of the compounds 
developed initially are suitable for testing on human subjects [3]. Due to such 
stringent control and safety and efficacy assessment it takes between 6-9 years for one 
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compound to enter the market as a marketable drug [1]. It can therefore be observed 
that there is a huge attrition in the number of compounds generated and number of 
compounds that enter clinical trials. The problem is further accentuated by the fact 
that the number of failures remains high even in phase 3 of development for example 
in the case of cancer over 50% of the drugs fail to progress.  This is mainly due to the 
fact that most in vitro screens do not pick up 90% of the toxicity [3]. Many of the 
compounds also fail due to unacceptable toxicity seen in many of the preclinical 
animal models.  These toxicities observed are not necessarily correlated with 
toxicities observed in humans due to interspecies differences in toxicological 
responses [4].  This fact is further supported by the failure of a number compounds in 
clinical trials due to adverse drug reactions mainly affecting vital organs like the liver, 
heart and kidneys.  
 
Figure 2: Reasons for drug failure a) NCE’s by large UK companies b) NCE’s 
excluding anti-infectives (Adapted with permission from Kubinyi et al [5]) 
Apart from toxicity to various organs many of the drugs also fail due to poor 
bioavailability, lack of efficacy, commercial reasons and pharmacokinetics as shown 
in Figure 2.  
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Current drug development paradigms mainly employ in vitro models using animal or 
human cells and preclinical studies involving various animal species for efficacy and 
safety assessment of compounds. However, there are a number of pathogens and other 
infectious agents, which can be studied only in humans and in biological material of 
human origin [6].  Use of animal models in preclinical testing and ethical issues 
involved with drug testing in humans makes it notoriously difficult to develop drugs 
targeting these pathogens. This is evident from the fact that over the years it has been 
extremely difficult to develop effective drugs or vaccines against hepatitis C, hepatitis 
B, HIV and various forms of influenza. However tremendous progress has been made 
to manage HIV and the FDA has recently approved 2 new drugs telaprevir and 
boceprevir to cure chronic hepatitis C of genotype 1 and 2.  
 
1.2 Need for in vitro models 
From these pitfalls observed with the current strategy, there is a huge unmet need for 
in vitro models for developing new drug entities and predictive toxicology. The 
concept of fail early, fail cheap will have considerable economic value to 
pharmaceutical companies.  
These models could also have tremendous implications by contributing to the 
understanding of the life cycle of various pathogens from early stages of infection all 
the way until capturing life cycle of the pathogen [7]. These strategies could be used 
to understand the pathophysiology of diseases at a molecular level and also aid in 
identification of novel targets and leads [8]. For various toxicology applications these 
models could aid in understanding mechanisms of toxicity and can aid in 
understanding the toxicity detected during preclinical studies. This information can be 
then obtained and rational drug design can be performed [9].   These models can also 
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be used to ascertain human risk during preclinical studies. Furthermore, they are more 
reproducible than in vivo models, easier to utilize and are popular since it necessitates 
the reduction of animals used during preclinical studies [10].  
These observed pitfalls of the current strategy despite the huge costs currently 
involved, has prompted huge investments into development of physiologically 
relevant and predictive in vitro models.  With the number of drugs losing their patent 
protection there is an urgent need to develop newer drugs in challenging areas of 
medicine and market analysts are forecasting a  $2.7 billion investment for these 
technologies by 2015.  
Among these the pharmaceutical industry contributes to a major part of the 
investment with a value estimated at $976 million by 2015 at an annual compounded 
growth rate of 19.5% (Figure 3). 
 
Figure 3: Global in vitro toxicology market estimates (Source: 
www.bccresearch.com) 
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Among the various in vitro models being developed to predict various organ toxicities 
in the pharmaceutical industry, a great amount of focus and efforts have been driven 
towards building predictive models of the liver; which plays a very vital role in 
maintaining normal homeostasis [11] and is subject to infection by various pathogens 
and  also plays an important role in the first pass metabolism of various xenobiotics.  
 
1.3 Structure function relationship of liver and hepatocyte microenvironment: 
The liver possesses an extremely efficient design. It consists of the reactor bed, a flow 
manifold and system, which deliver nutrients and metabolic products to the blood 
stream while shunting bile into the bile duct. The main functions are to remove toxins 
and to perform metabolic activity like cytochrome P450 based metabolism, glycogen 
storage, and to release cholesterol lipids and metabolic wastes. It also helps store iron, 
copper, fat-soluble vitamins and blood. In all there are more than 500 functions of the 
liver and many of them are very important to support life.  
 
Figure 4: Various liver functions  
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The two main competing views of the structural organization of the functional units of 
the liver are the lobule and the acinus [12]. Both models have hexagonal arrangement 
with the portal triads at the periphery and central vein at the centroid. In Kiernan’s 
proposed model blood enters the periphery from the digestive system through the 
portal triad and exits via the central vein after passing through the sinusoids.  The 
portal triad consists of 3 vessels carrying oxygenated blood from the heart via hepatic 
artery, portal vein carrying enriched blood from the intestines and bile duct carrying 
bile from the bile ducts. These structures branch out and supply and drain the entire 
liver.  
The acinar model proposes that the blood passes through the sinusoids and the oxygen 
content and nutrient concentration is varied based on contact of the blood with the 
hepatocytes. Therefore the cell types in the liver are heterogenous and whose 
functions differ as a result of composition of the contacted blood [12]. The acinus is 
divided into three zones based on oxygen concentration and distribution of nutrient 
concentration. Isolation of the sinusoid shows the functional fundamental unit of the 
liver a set of thin hepatocyte plates called acinus strung between the portal triad and 




Figure 5: Lobular model of the liver (Adapted with permission from 
Cunningham et al [13]) 
Further at the cellular level the liver has a very intricate organization, which might be 
necessary for achieving high levels of function. The acinus is organized as a sponge 
like structure which is perfused and has a plate of mature hepatocytes organized with 
single cell thickness knows as the parenchyma [14].   
These plates have 2 domains; the apical domain, which has the bile canaliculi and the 
basal domain, which is in contact with the ECM and sinusoidal blood.  These plates 
are lined by fenestrated endothelial cells, which create a physical and chemical link 
between the sinusoid and hepatic plate. Stellate cells traverse the region between the 
sinusoid and hepatic plate. The kupffer cells are interspersed between the sinusoids. 
The fluid flows mainly from the portal region to the central vein. Hepatocytes also 
form ducts known as bile canaliculi, which transport bile. These ducts are separated 
from the rest of the tissue by tight junctions.  
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Figure 6: Acinar model of the liver (Adapted from www.meddean.luc.edu) 
 
1.4 Cell types in the liver 
Four cell types, line the normal hepatic sinusoid each with specific phenotypic 
characteristics, functions and topography.  These cells participate in many disease 
processes and also various liver functions.  
1.4.1 Hepatocytes: 
Hepatocytes are highly differentiated cells, which are present in the liver. These cells 
contribute to over 60-65% of the liver population. They play vital roles in 
detoxification, secretion of plasma proteins, growth factors, metabolism of proteins, 
storage of fats, vitamins, iron and glycogen [15].  
1.4.2 Endothelial cells: 
Endothelial cells constitute the closed lining or wall of the capillary and make up 18-
23% of hepatic cells. They possess small fenestrations, which allow for diffusion of 
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O2 and other components, which allow for fat uptake. They also have very high 
endocytotic ability and also secrete bioactive factors and extracellular matrices [16].  
1.4.3 Kupffer cells: 
Kupffer cells are attached to the endothelial cells and line the sinusoids and represent 
8-12% of the hepatic cells. They are largest group of fixed cell macrophages in the 
body. These cells are potent initiators and regulators of inflammatory response and 
also have strong phagocytotic and endocytotic capacity [17]. They help in filtering out 
yeast and bacteria. Kupffer cells are more abundant in the periportal region. They are 
also the key source of plasma filtration [18]. 
1.4.4 Stellate cells: 
 The stellate cells lie in the space of disse and are also known as Ito cells. They 
represent 5-8% of the hepatic cell population. They are the main storage site of 
Vitamin A and are major producers of ECM [19]. These cells exist in 2 states in the 
liver; i.quiescent state where they appear like fibroblasts and store cytoplasm in the 
nucleus and ii. Activated state where they resemble myocytes [20]. Upon chronic liver 
disease or during fibrosis these cells secrete collagen and lead to the capillarization of 
the sinusoids [21].  
1.4.5 Oval cells:  
Oval cells are liver specific stem cells capable of self-renewal and multipotent 
differentiation and is usually found in the setting of chronic liver injury [22].  Oval 
cells are resident liver stem cells and are known to be atleast bipotent with an ability 
to differentiate into hepatocytes and cholangiocytes [23]. It is also known as the 
facultative stem cell during hepatocarcinogenesis.  
1.4.6 Pit cells: 
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Pit cells are liver associated lymphocytes and have the ability to kill tumor cells. They 
have a growth regulatory function in the liver. They are abundant in the periportal 
region of the liver [24].  
 
Figure 7: Different cells in the liver (Adapted with permission from Bataller and 
Brenner [25]) 
 
1.5 In vitro cellular models for drug development 
The choice of the cell type to be used for drug development application depends 
mainly on factors such as application and cost. In vitro cellular models are mainly 
used for early screening of toxic events and mechanistic evaluations of drug toxicity 
and propagation of liver specific pathogens [26]. However in vitro models have 
significant disadvantages like lack of systemic effects and absence of the ability to 
perform chronic dosing regimen [27, 28]. However, despite these shortcomings of in 
vitro models they are widely used in early phase drug discovery and development to 
better optimize leads.  
Most in vitro paradigms or endpoints obtained will be extrapolated to results observed 
in vivo to obtain correlations. Therefore the in vitro system or cell model being used 
should be as physiologically relevant as possible.  Over the years many models have 
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been developed or utilized for studying liver toxicity and to study the life cycle of the 
hepatitis C virus in vitro.  
Below is a schematic of the different in vitro models and the characterization of these 
based on application and practicality. 
 
 
Figure 8 :In vitro and in vivo models used in drug development (Adapted with 
permission from Brandon et al [29]) 
 
In genealogical order the various models used are  
a) Supersomes 
b) Microsomes 
c) S9 fractions 
d) Cell lines 
e) Primary hepatocytes 
f) Liver slices 
g) Perfused whole livers 
h) Animal models 
i) Humans 
j) Stem cell derived hepatocytes 
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Below is highlighted the advantages and the disadvantages of the various systems  
Cell model Advantages Disadvantage 
Supersomes • High throughput 
• One or more enzymes can be 
expressed 
• Cofactors required 
 
• UGT partially impaired 
Microsomes • High throughput 
• Phase I enzyme expression 
• Can be recovered from frozen 
tissue 
• Metabolite production 
• Drug inhibition, covalent binding 
and clearance studies can be 
performed 
• Several species available 
• Lacks phase II and 
cytosolic enzymes 
• Cofactors required for 
activity 
• Short term studies only 
• Diverse hepatic function 
absent 
S9 mix • Contains microsomal and 
cytosolic fractions 
• Phase I and phase II activity 
• Cofactors required 
• Lower enzyme activity 
compared to microsomes 
Liver cell lines • High throughput 
• Liver specific function 
maintained but at low levels 
• Easy to use 
• Easy availability 
• Lack in vivo phenotype 
• Low levels of liver specific 
phenotype 
• Mutations in various 
important pathways 
• Off target effects 
• Genotypic instability 
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Hepatocytes  • High throughput 
• Maintenance of differentiated 
function 
• Potential for use in long term 
toxicity, drug-drug interaction 
• Entire repertoire of liver specific 
functions 
• Human sample analysis possible 
• Viability and differentiation 
preserved for long culture periods 
• Survival and differentiated 
ability depends on culture 
condition 
• Special culture media 
needed 
• Batch to batch variability in 
samples 
• Difficult to source 
Liver tissue slices • In vivo cytoarchitecture 
• In vivo like expression of liver 
specific factors 
• Zonation can be studied 
• Tissue slices available easily 
compared to organs 
• Function lost within 24 
hours 
• Bile collection not possible 
• Necrosis at edges of slice 
• Low throughput 
Isolated perfused 
liver 
• Functions closer to in vivo 
• In vivo like expression of drug 
metabolizing enzymes and 
transporters 
• 3D architecture 
• Functional bile canaliculi 
• Low throughput 
• Function preserved for 2-3 
hrs 
• Human liver cannot be 
used 
• Complicated to use 
Stem cell derived 
hepatocytes 
• Easy availability 
• Disease specific phenotypes can 
• Low liver specific function 
• Expensive to generate 
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be obtained 
• Quality control tighter 
• High throughput 
• Non expression of lot of 
liver specific factors 
• Ethical issues with use of 
Embryonic stem cells 
 
Table 1: Various liver cell models and their advantages and disadvantages 
Modified from Brandon [29], Farkas [30] and Sivaraman [31] 
From the description obtained from the table above, it can be observed that primary 
hepatocytes obtained from different species provide a very good balance of 
throughput and cost and ease of handling. Further, primary hepatocytes also express 
the entire repertoire of components, which are responsible for drug metabolism, and 
to predict the entire life cycle of the drug once it enters the liver [32]. These cells also 
do not have mutations like some cell lines which interefere with the innate immune 
signaling pathway and thereby will allow for recapitulation of the true life cycle of the 
HCV in vitro [33] . The physiologically relevant cell model also allows for screening 
of anti-virals targeting this pathogen and allows us to estimate the efficacy of the 
compounds accurately. Thereby, due to these reasons primary hepatocytes are the 
most preferred models for in vitro drug development for applications related to the 
liver [34].  
Primary hepatocytes though physiologically relevant, are very hard to maintain once 
they are taken out of the liver environment [35]. In short, these cells are notoriously 
hard to maintain in vitro and lose their differentiated functions, viability and response 
to xenobiotics very rapidly in culture. This loss of differentiated liver function has 
hindered the use of these cells for various important applications and leads to lack of 
predictive drug testing.  
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In order to solve this bottleneck, various approaches have been used to maintain the 
integrity, morphology and differentiated phenotype of primary hepatocytes in culture. 
 
1.6 Tissue engineering approaches and paradigms 
Tissue engineering has followed the four-component paradigm of biomaterial 
scaffolds, cells, in vitro constructs, and applications of constructs whether in vitro or 
in vivo in a living host, for the past few decades, as reviewed by Griffith et al [36]. 
Each component is independently researched and the final applications depend on the 
available, off-the-shelf components. The approach is successful for engineering 
relatively simple tissues whose functional performance does not strictly depend on the 
detailed structural features. For example, early work on tissue-engineered skin led to 
commercial products that are in clinical use even today for covering the wound and 
preventing infection, without concerns for finer skin-features, such as wrinkles or hair 
follicles, that are important for aesthetics and perspiration, as reviewed by McNeil [37]. 
Liver tissue engineering research began with the development of hybrid liver-support 
systems [38] and cell-seeded scaffolds for stimulating liver regeneration [39]. These 
initial efforts employed a traditional top-down approach, in which cells are seeded 
into a macroscopic polymeric scaffold with feature sizes in the range of millimeters to 
centimeters [40]. The field has since progressed into more sophisticated bottom-up 
engineering approaches to address liver complexity; namely, vital organ functions that 
depend on the structural features at single-cell dimensions. Without fine control of 
these structural features such as bile canaliculi, sinusoids, cell shapes and polarity, 
tissue functions are not restored in predictable ways. The fine control requires 
precision engineering of the microenvironments in which the cells reside; such 
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microenvironments can be established with synthetic biomaterials, small molecules or 
neighboring cells. In a historically separate yet merged field of regenerative medicine, 
stem cells and stem-cell derived liver cells have been engineered for implantation or 
transplantation [41]. Therefore, the boundary between biomaterials and cellular 
engineering research has been blurred recently, as reviewed by Williams [42]. 
Liver tissue engineering applications currently consolidate into the following 
concerns: (i) toolbox (biomaterials, cells and constructs) development for precision 
liver tissue engineering and (ii) in vitro testing of xenobiotics (e.g. drugs and 
pathogens). Here is discussed the trends in these two areas, for rational tissue 
engineering approach for better maintenance of liver phenotype for the above 
mentioned applications. 
 
1.7 Toolbox development for precision liver tissue engineering in vitro 
Engineering microtissue constructs with bottom-up approaches for in vivo and in vitro 
applications requires the development of sophisticated biomaterials for cell assembly,  
microfabrication and nanotechnologies to precisely control the extracellular 
microenvironments, cellular shapes and inter-cellular tissue structures with intricate 
microscale features.  
1.7.1 Biomaterials for cellular assembly 
Cell-laden microgels have been developed to facilitate cell assembly into microtissue 
constructs in vitro [43, 44]. The microgels can be precisely controlled into desired 
orientation and shapes in a scalable manner [45]. It has been conceived that the 
microgels can interlock with each other to fuse into larger structures in which the cells 
can proliferate and remodel into complex tissue constructs as the microgel degrades 
[45, 46]. In situ photo-polymerization of cell-laden poly (ethylene glycol) (PEG)-
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based hydrogel has also been exploited for the construction of microtissue structures 
[47]. Hepatocytes suspended in a pre-polymer solution were photo-immobilized 
locally within a three-dimensional (3D) cell-hydrogel network, thus forming a 
functional 3D hepatic construct with complex internal features.  
Since liver is densely packed with cells supported by little extracellular matrices 
(ECMs), gel-free cell assembly with synthetic linkers [48] and cell-sheet engineering 
[49] offer potentially better control of microtissue construction. Synthetic linkers 
might serve as ‘cell glue’ to connect individual cells to form 3D multi-cellular 
constructs. Cell surfaces can be modified with non-native functional groups (e.g. 
aldehyde), which serve as reactive handles for attaching synthetic linkers, such as 
polyethyleneimine hydrazide [50] or dendrimer hydrazide [48]. Hepatoma-derived 
C3A cells were rapidly assembled into multi-cellular structures within one minute 
using a dendrimeric linker composed of oleyl- PEG derivatives conjugated to a 16-
arm polypropylenimine hexadecaamine dendrimer. The positively-charged linker 
stabilizes cell assembly by anchoring directly into the cell membrane via hydrophobic 
and charge interaction with the negatively-charged cell surface [51]. Mechanical 
constraints such as centrifugation and optical trap accelerate the formation of the 
linker-stabilized multi-cellular structures into defined shapes and patterns. Osahi et al. 
have developed another method to form uniform continuous hepatic cell sheet using 
isolated primary hepatocytes cultured on temperature-responsive surfaces [52]. At 
reduced temperature of 20°C where the surfaces turn hydrophilic to repel cells, the 
detached hepatocyte sheets can be stacked up to assemble into larger tissue constructs. 
In one study where hepatocytes and endothelial cells were co-cultured on dual 
patterned thermal-responsive polymers [53], heterotypic cell-cell interaction enhanced 
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cellular functions for 18 days. These biomaterials and simple yet versatile methods for 
cell assembly establish an essential toolbox for bottom-up liver tissue engineering. 
1.7.2 Micro- and nano-scale construct technologies 
Microfabrication and nanotechnologies precisely control the spatial distribution of 
biomolecules and substrate topography at micrometer to nanometer resolution. They 
can be utilized to engineer extracellular microenvironments, cell shapes and inter-
cellular tissue structures with intricate microscale features. One example is 
microfluidic channels in which hepatocytes are cultured in 3D microenvironments 
simulating the liver sinusoids of their cell-cell and cell-matrix interactions, soluble 
factor presentations, controlled mass transport and fluidic shear stress [54].  These 
devices not only improve cellular functions but also facilitate the culture of multiple 
cell types in a single device [54, 55]. Microstructures at the bottom surface of a 
microfluidic channel have recently been shown to restore long bile canaliculi 
structures and cell polarity in human hepatocytes [56]. Such surfaces of micro- and 
nano-scale are likely extendable to well-based culture plates for high-throughput 
xenobiotics testing. For multi-well plates, ultrathin (1-3 µm) silicon nitride 
membranes with uniform pore-size and even distribution were also microfabricated to 
improve mass transfer of nutrients and precisely control fluidic shear stress to 
perfusion-cultured hepatocytes. Other microfabricated devices were developed to 
precisely control homotypic and heterotypic cell-cell interactions in hepatocyte co-
culture with supporting cells such as fibroblasts [57, 58] that maintained high levels of 
hepatocyte functions for 42 days. Collagen, fibronectin or galactose ligands are 
typically conjugated to the cell-contacting surfaces of these microdevices to improve 
hepatocyte functions [58, 59]. 
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Nanofibers, nanopillars or nanotrenches, created with methods such as 
electrospinning and nanoimprint lithography, have been exploited to control cell 
shapes and alignment for optimal cell-cell interaction [60]. Ghibaudo et al have 
observed the transition of cell shapes from 2D to 3D when cultured on nanopatterned 
substrates [61]. We envision that these nanotechnologies will enable precision 
engineering of cellular shapes, polarity, spatial connection of bile canaliculi, and other 
liver tissue structures. The toolbox of the coming decade will likely migrate away 
from the cellular or multi-cellular resolution of the current technology toward sub-
cellular mesoscale (nm-mm) control in order to effectively recreate liver tissue 
microstructure and functions for in vivo and in vitro applications. 
 
Figure 9: Various technologies to engineer in vitro liver a) Microgels, b) 
Synthetic Linkers, c) Microfluidic devices, d) Nanopatterned substrates e) 




1.8 Purpose driven liver tissue engineering for applications. 
1.8.1 Pathogen testing 
Unavailability of efficacious vaccines owing to the lack of in vitro models to examine 
Hepatitis C virus (HCV) replication has drawn increasing attention. HCV can 
propagate in various hepatoma cell lines in vitro, but these models do not represent 
the true characteristics of virus infection. Conversely, primary human hepatocytes 
represent the most physiologically relevant model to study the disease in vitro as they 
exhibit polarized epithelial phenotypes in spatially localized extracellular polarity 
cues such as cell-cell and cell-ECM interactions [62]. The viral entry into cells is 
controlled by cell polarization and cellular localization of CD-81, CLDN-1 and 
SCRB-1 [63, 64]. This implies the need for properly reconstructed liver tissue features 
recapitulated in spheroids or micro-patterned co-cultures to achieve viral infection and 
replication in vitro [65, 66]. Future research should focus on screening novel 
therapeutics in these in vitro cultures and to determine if adaptive viral mutations in 
vitro are representative of that observed in vivo. Similar models can be developed to 
test Hepatitis A-E and other liver pathogens, such as Plasmodium falciparum. 
Repopulation of mouse liver with human hepatocytes have shown chimerism of up to 
96% [67]. These models have also been used to replicate HCV and HBV [67, 68] and 
to screen anti-viral drugs.  
1.8.2 Hepatotoxicity testing 
In the pharmaceutical industry, costs have driven safety testing toward the early 
stages of the drug discovery pipeline.  Twenty years ago, efficacy and potency of the 
pharmacological target were the sole aims, with Absorption, Distribution, Metabolism 
and Excretion (ADME) and toxicity/pathology determined toward the end of 
preclinical testing.  Today, lead compound selection and optimization usually includes 
32	  	  
assessment of cytotoxicity and, increasingly, characterization of hepatic ADME and 
toxicity in vitro. Typically, candidate compounds are available only in milligram 
quantities, so in vivo testing is not possible until one has selected a lead. 
Cryopreservation of human hepatocytes has made testing more convenient and has 
provided human-specific assays, particularly Cytochrome P450 enzyme  (CYP), 
transporter inhibition and induction assays, which often behave differently in human 
cells than in preclinical species such as rat, mouse and dogs. When compounds are 
metabolized differently, inhibit these enzymes, induce or repress the CYP’s and the 
transporters differently in humans, there is the potential for human toxicity and also 
for drug interactions.  
Unfortunately, many hepatocyte models were developed with only one or a few 
endpoints in mind.  For example, CYP induction and inhibition assays perform well in 
monolayer cultures, but gene expression analysis suggests pronounced changes in 
important biochemical pathways during culture that obviate the study of many other 
endpoints [69].  Similarly, sandwich cultures where hepatocytes are cultured between 
2 layers of collagen gel were developed to study canalicular transport, but often lack 
other enzymes, transporters and CYP’s that might be critical in the response to a 
studied compound [70]. A major issue with many hepatocyte models is their 
specialization; can they be generalized to detect other compound issues? While a 
model is often useful with only one purpose, a multiplexed model allowing many, 
often interacting endpoints is preferable.  
In addition to phase I metabolism (mostly well-established CYP’s) and transporters 
[70], there is increasing interest in phase II and oxidative stress/reactive metabolite 
(OS/RM)-protective enzymes [71].  Compounds and their reactive metabolites 
producing OS/RM generally activate the transcription factor Nrf2 that binds to the 
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antioxidant response element (ARE), which is common to the regulation of many 
conjugation and OS/RM-handling enzymes. Many idiosyncratic hepatotoxicants 
produce robust OS/RM, which are well handled by preclinical species and the vast 
majority of human patients. Inductions of OS/RM-protective enzymes are mostly lost 
in many hepatocyte models; although, covalent binding assays, glutathione 
conjugation assays, and an Nrf2-reporter assay have provided simplified assays for 
initially screening such compounds [72].  Reactive acyl glucuronides from non-
steroidal anti-inflammatory drugs seem to account for idiosyncratic hepatotoxicity; 
simplified chemical assays of the reactivity of these compounds is the present screen 
[73], but ignores effects that might dominate in hepatocytes.  
Incremental improvements in hepatocyte culture models often have profound effects 
on pharmacokinetic and toxicological screening of drug candidates, but occasionally 
major, fundamental changes are necessary.  Traditional media for hepatocyte culture 
contain high glucose levels (4.5 g/l, high diabetic levels), some have cautioned that 
mitochondrial respiration is inhibited by high glucose levels [74]. This is particularly 
important for screening potential mitochondrial toxicants, because most such 
compounds require ongoing mitochondrial respiration to exert their toxic effects.  
Increasingly, cell models have taken the place of animals in safety testing for 
cosmetics and pharmaceuticals. In the European Union in particular, there has been a 
concerted push to develop better in vitro models in response to new laws and statutes 
limiting animal use [75]. 
Models have been developed to predict different forms of liver toxicity. Zonation of 
the liver owing to differences in oxygen tension leads to variations in CYP expression 
levels and, in turn, differences in toxicity. Flat-plate bioreactors with co-cultured 
hepatocytes have been developed that mimic the differences in CYP expression 
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levels, leading to noticeable differences in toxicity within different zones in vitro [76]. 
Better prediction of acute toxicity has been demonstrated in microscale devices with 
tissue-like constructs in perfusion bioreactors [31]. These devices have demonstrated 
improved hepatocyte functions and sensitivity to CYP inducers, and matching in vitro 
and in vivo rates of testosterone metabolism [31].  
Microfluidic chips have recently been explored to determine the acute toxicity (IC50) 
and drug clearance of hepatotoxic drugs [77]. Spheroid cultures are garnering 
increasing attention owing to the ability to better-maintain cellular functions, but are 
hampered by their variable drug access characteristics due to hindered mass transfer 
to the spheroid core, mainly due to the uncontrolled spheroid size. A pre-spheroid 3D 
monolayer could address some of these issues [78] by the control of spheroid size, 
enabling better mass transfer. Chronic toxicity and inducibility are more difficult to 
study in vitro. Recently developed microscale co-cultured hepatocyte devices that 
expresses high levels of functionality for 42 days was used to study chronic toxicity 
[58]. The maintenance of bile canaliculi-like structures in the long-term culture 
enables the study of transporters and cytochrome-mediated interactions with enhanced 
accuracy. However, none of the above mentioned models predict idiosyncratic 
toxicity in vitro. Idiosyncratic toxicity has various underlying causes of which only 
the inflammation-mediated toxicity has been studied in vitro, though with low 
predictability [79]. Hepatocytes with inflammatory cytokines such as TNF-α, IL1α, 
IL-6, IFNγ [79], or co-cultured with kupffer cells, as reviewed by Dash et al [80] in 
the presence of lipopolysaccharides (LPS) were used.  These newly developed in vitro 
models should be exploited to enable better predictability on phase II and OS/RM 
enzyme responses to test a broader range of idiosyncratic toxicants. The trend of 
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testing drugs early would also require an abundance of high-quality cell sources in 
unison with platforms facilitating scalable and robust screening of drugs. 
Listed below are various tissue engineered liver models for various applications: 







Polarized cells to study drug 
metabolism, cytochrome induction, 
transporter activity, acute and 
idiosyncratic toxicity 
[78], [70] 
3D liver surrogate 
Fomation of aggregates 
(Spheroid cultures) 
3D cultures for study of chronic 
toxicity, acute toxicity, enzyme 
induction, maintenance of bile 
canaliculi like structures 
[69] 
Flat plate Bioreactor Perfusion based system with varying 





Shear mediated signaling by mimicking 
blood flow through the liver and allows 
for use of minute quantities of reagents 
[31] 
Micropatterned co-cultures Optimal homotypic and heterotypic 
interactions to study chronic toxicity, 
acute toxicity, drug interactions  
[58] 



























Liver tissue engineering has been driven by the need for in vitro models to better 
translate into applications such as developing better bio-artificial liver devices, 
models to study drug induced hepatotoxicity and infections of the liver in vitro. The 
design criteria and performance requirements for each one of these specific 
applications is vastly different. Many of the tissue-engineered models today have been 
developed to study one or few endpoints in mind and this limits the extrapolation of 
these models for multiple applications with optimal performance. Over the years 
many tissue-engineered models have been developed based on various principles. For 
extending these models for applications we need to understand how different 
engineered models compare for studying end points related to each application. Only 
then can the potential of primary hepatocytes in applications be realized.  
The objective of this thesis is two fold; i) To evaluate the potential of sandwich 
cultured rat hepatocytes and co-culture of rat hepatocytes and NIH 3T3 fibroblasts to 
study drug induced hepatotoxicity and CYP 450 induction and also the identification 
of the important soluble factor mediating this response. ii) Development of a spheroid 
culture of human hepatocytes to study HCV infection and replication in vitro.  
The rationale and hypothesis for each of these aims will be discussed in the following 
sections.  
 
2.1 Specific Aim 1:  
Develop a spheroid culture of human hepatocytes and Huh 7.5 cells with high levels 
of hepatocellular functions, polarity to study HCV infection and replication.  
2.1.1 Hypothesis: 
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Spheroid cultures enhance homotypic interactions between hepatocytes thereby 
facilitating the establishment of hepatocellular polarity and maintenance of 
hepatocellular phenotype allowing for higher HCV infection and replication.   
2.1.2 Rationale: 
Developing new drugs against HCV virus has been challenging due the non-
availability of physiologically relevant small animal or in vitro models, which 
recapitulate the life cycle of the virus. The current cellular model widely used to study 
the virus is the Huh 7.5 cell, which has an aberrant interferon pathway and is highly 
permissive to replication [7]. However, these cells exhibit low levels of infection in 
traditional monolayer cultures [81]. Primary hepatocytes with their entire set of 
hepatocellular functions are physiologically the most relevant models to study the life 
cycle of HCV and efficacy of anti-viral drugs. However, primary hepatocytes in 
traditional monolayer cultures rapidly lose their polarity and liver specific phenotype 
[58]. Spheroid cultures constructed using various methods have been shown to 
enhance and maintain long-term hepatocyte function and enable the establishment of 
hepatocellular polarity. The biggest drawback with the previous methods is non- 
uniformity and uncontrolled size of spheroids formed which leads to heterogeneity in 
responses. We aim to develop a system using cellulosic scaffold [82]	   where the 
spheroid sizes are uniformly controlled and the re-establishment of hepatocellular 
polarity along with the expression of viral entry markers will allow for the higher 
levels of infection and replication of HCV.  
2.1.3 Experimental design: 
The hepatocytes and Huh 7.5 cells were cultured in a cellulosic scaffold with uniform 
porosity to form spheroids of uniform dimension. Cells in monolayer were cultured 
using native collagen as ECM support. The long-term maintenance of hepatocellular 
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phenotype was evaluated by analyzing the transcript levels of various mature 
hepatocyte specific markers. The establishment of hepatocellular polarity and 
expression of viral entry markers was analyzed by immunostaining and confocal 
microscopy. The ability of the systems to support HCV infection was performed by 
infecting the cells with HCV pseudo particle and analyzing luminescence. The ability 
of the systems to support HCV replication was evaluated by infecting the cells with 
JFH-1 virus and detection of the negative strand of the HCV by real time PCR.    
 
2.2 Specific Aim 1:  
To evaluate the potential of sandwich cultured rat hepatocytes and co-culture of rat 
hepatocytes with NIH 3T3 fibroblasts to study drug induced hepatotoxicity and role of 
TGF-β1 (a soluble factor) in mediating these responses.  
2.2.1 Hypothesis:  
Enhancement of synthetic function and modulation of drug-induced responses in a 
hepatocyte fibroblast co-culture is primarily mediated by soluble factor mediated 
signaling.  
2.1.2 Rationale: 
In vitro evaluation of drug-induced hepatotoxicity over the years has relied on various 
cellular models among which primary hepatocytes are currently accepted as the gold 
standard to evaluate various forms of hepatotoxicity. Primary hepatocytes however 
are notoriously hard to culture in vitro while maintaining high levels of liver specific 
phenotype. Collagen-collagen sandwich of hepatocytes is currently the preferred 
model of choice to study drug induced hepatotoxicity, drug induction and drug 
interactions [83]; however this system falls short for the study of other end points 
such as evaluating OS/RM.  Co-culturing hepatocytes with non-parenchymal cells 
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such as NIH 3T3 fibroblasts have been previously shown to enhance and maintain 
hepatocellular function via heterotypic interactions and soluble factor mediated 
signaling [57]. Co-cultures of hepatocytes and NIH 3T3 fibroblasts are growing in 
prominence due to some of the advantages they offer, however are not accepted by 
the pharmaceutical industry for routine drug screening.  However, the evaluation of 
hepatocytes fibroblast co-culture to study hepatotoxicity and drug interactions has 
been not been thoroughly explored. Previously published results also have 
demonstrated that TGFβ1 is an important factor elevated in co-cultures [84].  This 
implies that this soluble factor plays an important role in mediating some of the 
effects observed in co-cultures. Therefore we aim to understand the utility of the 
collagen-collagen sandwich cultures and hepatocyte NIH 3T3 co-culture to study drug 
induced CYP 450 responses and evaluate if TGFβ1 is an important effector of these 
observed responses.   
2.2.3 Experimental design: 
Native collagen, which is usually used in hepatocyte cultures, was used to provide 
ECM support to hepatocytes and co-culture of hepatocytes and fibroblasts. The 
synthetic functions of the system was evaluated by measuring albumin secretion, urea 
synthesis and measuring the rates of metabolite production. Evaluation of drug-
induced responses was performed by drug-induced CYP 450 responses at both the 
transcript and activity level. Sensitivity of the systems to drug induced hepatotoxicity 
was analyzed using MTS assay using the paradigm hepatotoxicant APAP. The role of 
TGFβ1 in modulating synthetic function and drug-induced CYP 450 responses was 
analyzed by both reconstitution and depletion of TGFβ1 from native media and 
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Historically lack of effective vaccines or therapeutic options to combat HCV is 
mainly hindered due the host specificity of the virus and the lack of small animal 
models and the inability of in vitro models to support robust replication of all 
genotypes of the virus [85]. HCV primarily replicates in human liver hepatocytes in 
vivo however there has been a dearth of in vitro models to study the virus. Initially, 
hepatitis C virus replication in human hepatoma cells needed cell culture adaptive 
mutations of the virus and therefore the initial understanding of the nature of the viral 
host interactions is based on replication of genomic and sub genomic replicons [86] 
which did not capture the entire life cycle of the virus and does not release infectious 
particles of the virus. Many of the drawbacks in understanding the replication and life 
cycle of the virus in vitro were solved with the identification and the replication of the 
JFH-1 replicon; a full-length genomic clone, which does not requires adaptive 
mutations for it to replicate in culture [87].  These advances have allowed for the 
replication of the full length HCV virus in human hepatoma cells namely Huh 7 and 
Huh 7.5 and helped gather a great amount of insight into host pathogen interactions 
[88]. Further, consensus sequences, which are infectious in vivo are not infectious in 
cell culture. This issue is more perplexing for genotype 1 strains, for which even 
accumulation of cell culture adaptive mutations results in low yields of HCVcc with 
impaired infectivity, which has made the study of this disease even harder. Though 
the hepatoma cells support replication of the virus, these cells display aberrant 
signaling of various interferon pathways and have deregulated gene expression.  This 
results in the inability to study physiologically relevant responses in this system. 
Primary hepatocytes with their complete set of viral entry receptors and phenotype 
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similar to that of in vivo liver are therefore noted to be the most suitable cell model 
for studying HCV infection [66] and antiviral drug screening in vitro 
Liver specific cell lines used for HCV replication exhibit very low levels of liver 
specific functions and primary human hepatocytes though physiologically relevant are 
notoriously hard to maintain with high functionality in in vitro cultures [89]. Over the 
last decade various strategies like microscale technologies, fluid flow, spheroid 
cultures, co-cultures with non-parenchymal cells and varying extracellular matrices 
have been used to improve the differentiated status of hepatic specific cell lines and 
also prolong the viability and functionality of primary hepatocytes in culture, though 
not all these systems work with both cell lines and primary hepatocytes [58, 90].   
Among the various different strategies employed for tissue engineering, spheroid 
cultures allow for tight homotypic interactions and high E-cadherin expression [91] 
and therefore longer maintenance of phenotype in culture.  The cells cultured in the 
spheroid configuration are known to behave differently to various stimuli and are also 
morphologically and transcriptionally distinct compared to 2D cultures [91].  Various 
iterations of spheroid cultures for culturing human and rat hepatocytes have helped 
maintain higher order differentiated functions over prolonged cultures [69]. However, 
the greatest drawbacks of these systems is the uncontrolled size of the spheroids 
which leads to hypoxia at the spheroid core, limited access to drugs and nutrients, 
difficulty in handling these constructs, which leads to heterogeneity of responses 
which is made evident in downstream assays [82]. Further the current systems are also 
very difficult to scale and adapt to conventional multiwell platforms for routine drug 
screening.  
Here we aim to demonstrate the utility of a thin galactosylated cellulosic sponge of 
1mm thickness with controlled macroporous structures to culture Huh 7.5 cells and 
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primary human hepatocytes as spheroids in a multi-well platform to support HCV 
infection and replication. 
 
3.2 Background: 
Hepatitis C infects over 3% of the worlds population and more than 170 million 
people have been infected worldwide [92]. Most of the hepatitis C infections become 
chronic and lead to liver cirrhosis, liver cancer and end stage liver failure [92]. The 
current line of treatment involves the use of IFN/ribavirin for the treatment for 
hepatitis C, and does not work effectively against many genotypes of the virus, 
however the launch of 2 new drugs against this virus seems promising namely 
Bocepravir and Telapravir which inhibit the viral proteases [93, 94].  Over 10,000 to 
20,000 deaths a year are due to Hepatitis C and it is the leading cause of liver 
transplant in the USA [95].  Despite the discovery of the virus way back in 1989 and 
the complete elucidation of the genomic structure of the virus, little has been known 
or discovered about the nature of the protective immune responses.  
This virus belongs to the Flaviviridae family of viruses and is a non-cytopathic virus. 
[96]. It is primarily transmitted percutaneously like hepatitis B and HIV. Today the 
main cause of hepatitis C transmission is by sexual contact or by drug users using 
infected syringes and by blood transfusions in developing countries [97]. This virus is 
opportunistic in HIV infected individuals and co-infection of HCV and HIV leads to 
faster progression of liver cirrhosis [98].  
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Figure 10: History of Hepatitis C infection (Adapted with permission from 
Chisari et al [92]) 
 
 3.3 Hepatitis C virus and host interactions: 
Hepatitis C virus infects only humans and chimpanzees. This virus specifically infects 
the liver of these species and replicates in the liver.  Lack of small animal models 
have made it difficult to understand the life cycle of the virus though current in vitro 
models have provided us a wealth of information regarding the mechanism of virus 
entry and replication since its discovery in 1989 [99].  
Hepatitis C genome is a 9.6 kb uncapped linear single stranded RNA with positive 
polarity. It encodes 3000 a.a, which is cleaved into structural and non-structural 
proteins by proteases. Structural proteins (C, E1, E2, p7) help in formation of the viral 
particle while the non-structural components (NS2, NS3, NS4A, NS4A, NS5A and 
NS5B) are involved in the replication of the virus [100, 101]. The infectious virus 
particle is composed of a nucleocapsid or ribonucleoprotein complex bearing the 
HCV genome; this inner structure is surrounded by a phospholipid bilayer, into which 
E1 and E2 envelope glycoproteins are anchored. The infectious viral particles are 
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often found in association with VLDL [102]. Viral entry is defined by the binding of 
the virus to hepatocytes to the delivery of the genome to its replication site. 
 
3.4 Viral proteins mediating entry: 
Several cell surface proteins, such as tetraspanin CD-81, SCARB-1, claudin-1 and 
occludin-1 are considered to be essential receptors or co-receptors for Hepatitis C 
virus cell entry. In addition to these heparan sulfate, LDL receptors and SIGN have 
been implicated in cell attachment and entry.  
3.4.1 CD-81:  
CD-81 is an unglycosylated membrane protein belonging to the tetraspanin family of 
proteins. It contains 4 transmembrane domains, 2 small and 1 extracellular loop and 1 
N-C terminal intracellular domain [103].  It is needed for normal expression of CD19.  
CD-81 has been proposed as an important receptor for viral entry.  The large 
extracellular loop of CD-81 is known to bind sE2 subunit of HCV [104]. This 
interaction is known to be species specific where the sE2 binds specifically to Human 
CD-81 and no interaction has been observed with rat and mouse CD-81 [105]. The 
critical role of CD-81 in HCV entry has been proven by many experimental 
approaches where HepG2 and human hepatoma cells become susceptible to HCV 
entry after ectopic expression of CD-81 [106]. The HCV E2 binding region maps to 
the LEL domain of CD-81. Use of antibodies directed against CD-81 and also soluble 
form of CD-81 LEL inhibited HCV entry in vitro.  Silencing of CD-81 and use of 
other antibodies against CD-81 also inhibit HCV infection [107].  
Several groups have hypothesized that CD-81 is a post binding entry receptor [108].  
Antibodies against CD-81 inhibit infection only after viral attachment. Susceptibility 
to infection with this virus is dependent not only on the expression of CD-81 but also 
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expression of and SCARB-1 on cell surface [106].  EWI-2wint is an important 
molecule, which interacts with CD-81 and blocks viral entry. The absence of this 
molecule in hepatocytes could be the reason for the hepatotropism of the virus [109]. 
HCV binding to CD-81 triggers a number of pathways necessary for viral infection. 
Binding of CD-81 and the virus leads to activation of Rho-GTpases and relocalisation 
of CD-81-E2 complex to cell-cell contact areas. The binding also activates 
Raf/MEK/ERK pathways, which affect post entry steps of the virus [110]. Further, 
CD-81 activated adaptive immune responses through interaction with T and B cells 
and might be responsible for virus persistence and extrahepatic manifestation 
observed in chronic hepatitis patients [111].  
3.4.2 SCARB-1: 
SCARB-1 is expressed in mammalian cells and highly expressed in the liver and 
stereogenic tissues. It is a glycoprotein with 2 cytoplasmic and 2 transmembrane 
domains and large extracellular loop [112]. It is a multiple ligand receptor, which 
binds to many ligands namely HDL, LDL and VLDL and chemically modified LDL.  
It plays an important role as an endocytic receptor and its important role is the uptake 
of cholesteryl ester from HDL. This receptor plays a role in reverse cholesterol 
transport by mediating cholesterol efflux to HDL [113, 114]. Further this receptor also 
plays a role in the catabolism of VLDL and selective uptake from VLDL.  
SCARB-1 has been suggested to be a putative molecule for HCV entry. It facilitates 
this entry by binding to the sE2 domain of the virus. [115]. This interaction seems to 
be species specific.  The HVR-1 region of the virus E2 is responsible for the binding 
to SCARB-1 [116]. Addition of antibodies against SCARB-1 or deletion of HVR-1 
region leads to inhibition of virus entry. SCARB-1 also acts a post binding receptor 
[116].  
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HDL though a major ligand of SCARB-1 is known to enhance HCV entry [117]. 
However, there is no known interaction with HDL and the virus particle that has been 
demonstrated. There have been proposed mechanisms, which suggest that HDL 
enhances viral entry by activating the SCARB-1 receptor. In contrast to HDL; LDL 
and VLDL inhibit viral entry [118].  
Several studies suggest that SCARB-1/claudin1 cooperatively interact with CD81 in 
HCV entry [106]. HDL enhanced HCV infectivity only when CD81 was expressed.  
Further SCARB-1 has the ability to alter the arrangement of the plasma membrane 
acting as a cholesterol provider and regulating the arrangement of CD-81 thus 
modulating HCV entry. The role of SCARB-1 was further confirmed when antibodies 
directed against SCARB-1 ameliorated entry and expression levels of SCARB-1 also 
modulate viral entry. SCARB-1 binds to serum amyloid A (SAA), which is released 
by hepatocytes during acute infection and this protein inhibits viral entry. 
Interestingly HDL binds to SAA and has a negative effect on antiviral effect of SAA. 
Further, treatment with interferon is known to reduce the expression of SCARB-1 on 
the cell surface thus restricting viral attachment and entry. 
3.4.3 Claudin-1: 
Evans et al have identified a member of claudin gene family to be involved in HCV 
entry [119]. This molecule is expressed in all epithelial tissues but predominantly in 
the liver forming networks at the tight junctions [120]. It is a 211 a.a protein 
containing 2 extracellular domains, 4 transmembrane segments and 3 intracellular 
domains [121]. The highly conserved domain in extracellular loop is responsible for 
HCV entry.  
The expression of Claudin-1 in 293T cells and SW13 have been shown to confer 
susceptibility to the virus [119]. Silencing of claudin-1 inhibits HCV entry in 
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susceptible cells [122].  However there has been no direct interaction of the virus with 
claudin-1 protein. One of the proposed mechanisms of interactions is, the 
translocation of the CD81/SCARB-1/virus complex from the basolateral domain of 
the hepatocytes to the apical domain where it interacts with claudin-1 [64].  
Other members of the claudin family namely claudin-6 and 9 also mediate HCV entry 
[122]. Recent data also confirms the distribution of claudin-1 in the tight junction 
correlates with the permissiveness to HCV infection thus showing the importance of 
claudin in viral entry and its contribution to the cellular tropism of the virus.  
3.4.4 Occludin-1: 
Occludin-1 has been shown to be an important factor for the entry of HCV virus into 
hepatocytes [123]. However it has been observed that expression of claudin-1 in CD-
81 and SCARB positive cells does not render the cells susceptible to infection [124]. 
This suggested that there are other factors responsible for viral entry. Recent studies 
have shown that another trans membrane protein at the tight junctions is responsible 
for the HCV entry and initiation [123]. Occludin is a 60kDa protein with four 
transmembrane domains, 2 extracellular loop and a N-C terminal cytoplasmic regions. 
It participates in cell-cell adhesion and anchoring of junctional complexes to the 
cytoskeleton [125]. Targeting claudin and occludin by si and sh RNA showed the 
reduced expression of these proteins resulting in decreased HCV entry [126]. Some 
data also suggests that expressing occludin in murine cells makes them susceptible to 
HCV entry and infection. This suggests that there is a direct interaction with occludin 
and E2 glycoprotein of the virus and facilitates entry via the tight junctions [126]. It 
has been shown that HCV infection alters the localization of tight junction proteins 
[127]. The expression of tight junctions proteins is also downregulated following 
infection to prevent super infection.  Tight junctions are necessary to maintain the 
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polarity of the hepatocytes and altered localization and expression might lead to 
problems like portal hypertension, cholestasis. 
 
3.5 Mechanism of viral entry: 
 
Figure 11: Mechanism of viral entry. (Adapted with permission from Burlone et 
al [118]) 
After attachment of the virus to cell surface proteins, HCV is translocated to the tight 
junctions where it interacts with occludin and claudin. Here, it is taken up via clathrin 
mediated endocytosis (Fig 11). This process is pH dependent with an optimum pH of 
5.5. E1 and E2 are fusion proteins and fusion process leads to the formation of a 
fusion pore. However none of the HCV receptors have been shown to mediate viral 
fusion [128]. Recent data shows that viral entry could also be dependent on the 
microtubule network [129].  
Apart from these receptors various LDL, apolipoproteins and GAG’s are known to 
play a key role in the presentation of the virus and in viral entry.  
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3.6 Hepatitis C replication: 
Upon viral entry mediated by clathrin mediated endocytosis there is a fusion of the 
viral and cellular membranes, which leads to the release of positive stranded RNA 
into the cytoplasm of the newly infected cell.  This serves various functions namely as 
an mRNA template for protein production, template for RNA replication and nascent 
genome packed with new viral particles.  
 
 
Figure 12: HCV life cycle (Adapted with permission from Moradpour et al [138]) 
  Translation of HCV that lacks the 5’ end cap depends on internal ribosome entry site 
(IRES) within the 5’ non-coding region.  The HCV IRES binds 40S ribosomal subunits 
directly and induces an mRNA-bound conformation in the 40S subunit [130]. The IRES–
40S complex recruits eukaryotic initiation factor (eIF) 3 and the ternary complex of Met-
tRNA–eIF2–GTP which ultimately forms the translationally active 80 S complex via a 
non-canonical 48 S inter- mediate [131].  The translation of the HCV genome produces a 
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large polyprotein that is cleaved to produce 10 viral proteins. The amino-terminal of the 
polyprotein encodes the virion structural proteins: the highly basic core (C) protein, and 
glycoproteins E1 and E2. After the structural region comes a small integral membrane 
protein, p7, which seems to function as an ion channel [132]. The remainder of the 
genome encodes the nonstructural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A and 
NS5B, which control the viral life cycle. The structural proteins mature by signal 
peptidase cleavages between C/E1, E1/E2 and E2/p7. Signal-peptide peptidase releases 
core from the E1 signal peptide. The p7/NS2 junction is also cleaved by signal peptidase. 
Further proteolytic processing within the NS region occurs through the action of two 
viral enzymes, the NS2 autoprotease, which cleaves at the NS2/3 junction; and the NS3-
4A serine protease, which cleaves at all downstream sites. HCV also encodes a small 
protein, called F (frame shift) or ARFP (alternative reading frame protein), that can be 





Figure 13: Structure of HCV virus adapted with permission from Moradpour et 
al [134] 
             
 3.7 HCV proteases: 
 3.7.1 NS2-3 protease: The NS2-3 protease is a difficult protein to study but it is an 
important protein indispensible for the replication and life cycle of the virus in vitro 
and in vivo [135]. The catalytic activity depends on 1/3rd C terminal of NS2 and N 
1/3rd terminal of NS3 [136]. NS2 has been shown to be associated with intracellular 
membranes. Its N terminal contains at least one transmembrane segment. The 
catalytic activity is mediated by His143, Glu163 and Cys184 [137].  Solving the 
structure of the N-terminal membrane domain of NS2 might yield insights into 
additional functions of NS2, which was recently found to be essential for the 
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production of infectious virus, possibly by affecting a late step of the viral lifecycle 
[135].  In vitro models supporting entire viral life cycle will help further elucidate the 
role of this protease. 
3.7.2 NS3-4A protease:   
NS3 is a multifunctional protein with C terminal serving as a serine protease and N 
terminal acting as a RNA helicase/NTPase.  The 4A polypeptide acts as a cofactor for 
NS3 and facilitates the integration of the NS3-4A complex to the intracellular 
membrane [138].  
The serine protease is often a target against which antiviral drugs are designed [139].  
The active sites are His57, Asp81 and Ser139. This protease has a shallow substrate 
binding pocket and therefore it has made it a challenge to develop substrate inhibitors 
to this protease. This protease activates adaptor proteins for immune sensing namely 
TRIF and CARDIF [140, 141]. A minor amount of this protease also localizes at the 
mitochondria, which might have implications for persistence and pathogenesis of the 
disease [142].  
The NS3 helicase is a member of the superfamily 2 DExH/D-box helicases. It couples 
unwinding of double-stranded RNA, or of single-stranded RNA regions with 
extensive secondary structures, to ATP hydrolysis. It was recently shown that NS3 
unwinds RNA through a highly coordinated cycle of fast ripping and local pausing 
that occurs with regular spacing along the duplex substrate [143]. Although it is an 
appealing target for antiviral drugs specific inhibitors for this region are not very 
prevalent.  There also seems to be evidence of cross talk between the serine protease 
and helicase region of the virus [144].  
3.7.3 NS4B:  
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NS4B is a 27kDa protein whose functional role is not well elucidated yet. One of its 
major functions is to form the membranous web, which serves as a scaffold for HCV 
replication [145]. Detailed membrane topology and the role of oligomerization in this 
protein are still not clear.  
3.7.4 NS5A:  
NS5A is a phosphoprotein that can be found in phosphorylated and 
hyperphosphorylated state. Phosphorylation of NS5A is conserved across 
hepaciviruses and pestivirus, thus it can be hypothesized that this protein plays a 
important role in the HCV lifecycle. Cell culture adaptive mutuation of the virus seem 
to affect this region responsible for hyperphosphorylation further strengthening this 
fact. Hyperphosphorylation is known to affect the interaction of the NS5A with 
vesicle associated membrane protein associated protein. This helps the interaction of 
these proteases with lipid rafts, which promote replication.  
NS5A is a protein attached to the membrane by an N-terminal amphipathic α-helix. 
This helix has a hydrophobic, tryptophan-rich face that is rooted in the cytosolic 
membrane interface, whereas the polar, charged face is exposed to the cytosol and is 
maybe involved in specific protein–protein interactions that are essential for the 
formation of a functional HCV replication complexes.  
3.7.5 NS5B: HCV replication proceeds by the synthesis of the negative 
complementary strand using HCV genome as a template. The most important enzyme 
responsible for this is the NS5B polymerase. The HCV RdRp is a so-called tail-
anchored protein. Membrane association is mediated by the C-terminal 21 amino-acid 
residues, which are dispensable for polymerase activity in vitro but indispensable for 
RNA replication in cells. Membrane targeting occurs by a post-translational 
mechanism and results in integral membrane association of NS5B [146]. 
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3.8 Viral replication complex:   
Positive stranded RNA viruses form very distinct membrane associated replication 
complex consisting of viral proteins, RNA and altered cellular membrane. Role of 
membranes in viral replication however is not very clear but it is said to be associated 
with providing stability or anchor for the replication machinery [147].  
The replication of the HCV replicon in Huh 7 cells produced led to specific 
membrane alteration known as membranous web [148]. Formation of membranous 
web is by the NS4B protease and this membranous web appears like sponge like 
inclusions and is derived from the ER.  
Studies have shown complex and tight interaction between HCV replication and 
cellular lipid metabolism.  Replication is increased by mono and unsaturated fatty 
acids and decreased by polyunsaturated fatty acids. It is also known that 
geranylgeranylation of some proteins is necessary for replication of HCV [149].  
Other factors for like cyclophilin A have also been implicated in the replication of 
HCV [150]. 
 
3.9 Packaging and assembly: 
Very little is known about late steps of the viral lifecycle. NS-2 and other possible 
non-structural proteins are said to be involved in this process. Virions are 
hypothesized to form by budding into the ER, or an ER-derived compartment, and 
exit the cell through the secretory pathway. A possible link between lipoprotein 
metabolism and viral assembly and release has been proposed [151]. 
 
3.10 Evasion of host defenses by the virus: 
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The difficulty in treating the virus has also been due to the ability of the virus to evade 
host immune responses, which it does by the following ways: 
 
 Viral strategy Mechanism of action Implication 
IL-8 induction NS-5A induces IL-8 via 
NF-κB and AP-1 
Attenuates IG expression 
SOCS induction SOCS 1 and 3 are induced 
by HCV proteins 
Inhibits JAK-STAT 
signaling through IFN- α 
and β 
PKR inhibition NS 5A and E2 inhibit PKR 
by binding 
Disruption of PKR 
pathway  
IRF-1 regulation NS5A blocks ds RNA 
activated IRF-1 action 
through PKR disruption 
Relieves IRF suppression 
of HCV replication 
Disruption of STAT 1 HCV proteins Hypomethylation of 
STAT1 reduces ISG 
expression 
Regulation of RIG-1 NS3/4A protease blocks 
signaling 
Prevents amplification of 
IFN signaling. 
Regulation of TLR-3 NS3/4A protease cleaves 
TRIF blocking TLR-3 
Disruption of IFN 
amplification loop 
Table 3: Viral evasion strategies 
 
Based on the background described the complexity and the factors necessary for HCV 
entry and replication machinery is highlighted. These details enable us to define 
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conditions and parameters to measure and characterize the in vitro system to study 




3.11.1 Huh 7.5 culture:  
Huh 7.5 cells were propagated in DMEM (high glucose) media supplemented with 1X 
minimal essential amino acids and 10% FBS. Cells were passaged at 80% confluence. 
Cells were sourced from ATCC.  
3.11.2 Human hepatocyte culture:  
Human hepatocytes were maintained in Williams E media supplemented with 1 
mg/mL BSA, insulin transferrin and selenium, 50 ng/mL linoleic acid, 50 nM 
dexamethasone and 100 U/mL of pencillin streptomycin. Cryopreserved human 
hepatocytes were sourced from commercial vendors Invitrogen and Becton 
Dickinson. 
3.11.3 Cell seeding and estimation of spheroid number: 
For both Huh 7.5 and human hepatocytes, 0.1 million cells (6mm scaffold) and 0.3 
million cells (9mm scaffold) were   reconstituted in 16µL or 60 µL of media and 8µL 
or 30 µL was added to either side of the sponge. After 45 min incubation at 37 ºC to 
allow the cells to enter the scaffold, 300 µL or 500 µL of respective media was added 
to each well and cells were incubated at 37 ºC. To measure the total number of 
spheroids in the scaffold, the scaffold was disrupted using a needle and the spheroids 
were released into the media.  The total number of spheroids in the given volume 
media was counted and this was extrapolated to number of spheroids per 1mm3 of the 
scaffold based on scaffold volume.  
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3.11.4 Synthesis of cellulosic scaffold: 
Hydroxypropyl cellulose (HPC), Mw = 80,000 g/mole and ~3.4 degree of 
etherification was dehydrated by azeotropic distillation in toluene at 70°C. 4 grams of 
dried HPC was dissolved in anhydrous chloroform (100 mL), to which 2.095 mL allyl 
isocyanate 98% and 1 mL dibutyn dilaurate 95% were added dropwise. The mixture 
was stirred vigorously for 48 hours at room temperature, after which it was 
precipitated in an excess amount of anhydrous diethyl ether. Following vacuum 
drying, the product was dissolved in deionized water (DI H2O), purified by dialysis 
for 3 days, and finally lyophilized to the end product, HA (Hydroxypropyl cellulose 
allyl). HA was dissolved in deionised water to a final concentration of 10 % wt/vol 
after which the solution was inserted into glass tubes (diameter 6 mm, length 3 cm). 
The tubes were heated in a water bath (40°C) until phase separation occurred, and 
then crosslinked by γ irradiation for 1 hour at a dose of 10 kGray/hour (Gammacell 
220, MDS Nordion, Canada). The sponge monoliths were obtained by breaking tubes 
subsequent to freezing in dry ice. A krumdieck tissue slicer (Alabama Research & 
Development USA) was used to cut the sponge uniformly (50 rpm for 1 mm 
thickness), denoted as HA sponges. 
The sponges were further modified with galactose by activating the hydroxyl groups 
with the addition of 1,1’-carbonyldiimidazole (20 mM in acetone) for 24 hours. D-
(+)-galactosamine HCl (2 mg/mL in carbonate-bicarbonate buffer) was added to the 
activated sponges.  The reaction was carried out for 24 hours at 4°C. To remove 
impurities, the sponges were further washed three times in excess of Dulbecco 
phosphate buffer saline and deionized water, subsequently. The washed sponges (HA 
Gal sponges) were lyophilized and sterilized with γ irradiation. 
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Figure 14: Materials synthesis A) Chemical synthesis steps, B) Schematic 
diagram of galactosylated cellulosic sponge preparation and C) 1H NMR 
spectrum of galactosylated cellulosic sponge in d6-acetone (Adapted from 




3.11.5 Scanning Electron Microscopy:    
Hepatocyte spheroids in sponges were fixed with 3.7% paraformaldehyde overnight 
and stained with 1% OsO4 for 1 hour. Samples were then dehydrated step-wise with 
ethanol (25%, 50%, 75%, 90% and 100%) for 10 min each, dried in a 37°C dry oven 
and sputter-coated with platinum for 90 s. The samples were viewed with a scanning 
electron microscope (JEOL JSM-5600, Japan) at 10 kV. 
3.11.6 Live/Dead staining: 
Hepatocytes spheroids were co-stained with Cell Tracker Green (CTG, 20 µM) 
(Molecular Probes, USA) and Propidium Iodide (PI, 25 µg/mL) (Molecular Probes, 
USA) to quantify live and dead cells, respectively. Cells were incubated for 30 min at 
37 °C and then fixed with 3.7% paraformaldehyde for 30 min at room temperature. 
Fluorsave (Merck Chemicals) was applied to the stained spheroids to minimize photo-
bleaching. Images were acquired by confocal laser scanning microscopy (Zeiss 
LSM510, Germany) at 488 and 543 nm excitation wavelengths. 
3.11.7 Immunostaining:  
Cells were fixed with 3.7% Paraformaldehyde for 15 minutes at 37 ºC followed by 
washing with 1X PBS.  Following washing and blocking with 2% BSA/0.2% Triton-
X 100, the spheroids were incubated overnight at 4 ºC: mouse anti-human CD-81 
(clone JS-81, BD Pharmingen; 1:100), rabbit anti-SCARB1 (NB110-57591, Novus 
Biologicals; 1:100), rabbit anti-CLDN1 (51-9000, Zymed; 1:100), rabbit anti-OCLN 
(33-1500, Invitrogen; 1:100), rabbit anti-MRP2 (Clone M2III-6, Sigma; 1:50) and 
Luciferase (AbCam, 1:100). Secondary antibodies used were goat anti-mouse and 
goat anti-rabbit 488 and 555, respectively. Nuclei stain was captured using mounting 
medium containing DAPI stain (Vecta Shield). Images were captured using Olympus 
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fluoview FV1000 with a 60X water lens. Images were analyzed using IMARIS and 
images assembled using Adobe illustrator CS2.  
3.11.8 Real-time PCR: 
RNA was extracted from hepatocytes cultured as 3D spheroids in HA Gal sponges 
using the Qiagen RNeasy kit. Total RNA concentration was quantified by using 
Nanodrop (Thermo scientific) and 1 µg of RNA was converted to-cDNA by high 
Capacity RNA-to-cDNA kit (Applied Biosystems). Primers were designed using 
Primer 3 and real-time PCR was performed by using SYBR Green fast master mix in 
an ABI 7500 fast real-time PCR system (Applied Biosystems).  
Gene Primer 
AAT F: GTCAAGGACACCGAGGAAGA 
R: TATTTCATCAGCAGCACCCA 
HNF4α F: TGTACTCCTGCAGATTTAGCC 
R: CTGTCCTCATAGCTTGACCT 






CYP1A1  F: CTTCACCCTCATCAGTAATGGTC 
R: AGGCTGGGTCAGAGGCAAT 
GAPDH F: GAGTCAACGGATTTGGTCGT 
R: GACAAGCTTCCCGTTCTCAG 
Table 4: List of human hepatocyte specific primers 
 
3.11.9 HCVpp synthesis:  
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The pseudoparticles were synthesized by co-transfection of plasmids encoding 1) E1 
and E2 HCV glycoproteins 2) HIV lacking the nef and env genes and containing the 
luciferase gene into 293T cells. 
3.11.10 HCVpp entry and inhibition assays:  
After 3 days of culture the human hepatocytes and Huh 7.5 spheroids and monolayer 
were subjected to treatment with 100 µL of media containing 1.5X DMSO and 1.5X 
penicillin streptomycin with or without CD-81 at various concentrations.  To this 
media HCV pseudoparticle was added at same MOI for monolayer and spheroid 
cultures. End points of viral entry were measured 3 days post infection by 
immunostaining and luciferase assay measuring total luminescence (Promega Steady-
Glo kit) and normalized to total protein using Nanoorange protein quantitation kit 
(Invitrogen). 
3.11.11 Quantifying viral replication: 
Viral replication was carried out using JFH-1 strain of HCV virus. The cells were 
infected with JFH-1 strain of the virus after 3 days of culture for 2 days, following 
which the media was changed every 2 days and cells lysed every 2 days and the RNA 
isolated using perfect pure RNA cell vac kit (5 prime). The RNA was isolated and 
purified and copy number of the virus was quantified using Real time PCR. 
Comparison of copy number between monolayer and spheroid was performed by 
normalizing it to β-actin.  
 
3.12 Results: 
3.12.1 Characterization of spheroids in the scaffold: 
Both Huh 7.5 and human hepatocytes form spheroids in 24 hours. The scaffold allows 
for uniform distribution of spheroids for both Huh 7.5 cells and human hepatocytes. 
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They form approximately 17 spheroids per mm3. This means we have around 1300 
spheroids in a 10mm diameter scaffold and 500 spheroids in a 6mm scaffold (Table 
5). Each spheroid has approximately 100 cells and the total cell number allows for 
good sensitivity in downstream assays.  
 
Number of spheroids per unit volume 
(mm3) 
~17 
No of spheroids in a 10mm scaffold (24 
well plate) 
~1300 
No of spheroids in a 6mm scaffold (48 
well and 96 well plate) 
~500 
 
Number of cells per spheroid ~100 
 Image of the scaffold with cells 
 
Table 5. Characterization of spheroid number in cellulosic scaffold 
Both Huh 7.5 cells and human hepatocytes formed tight spheroids within 3 days and 
maintained their spheroid configuration over prolonged culture. We characterized the 
spheroid size distribution of the Huh 7.5 and human hepatocyte spheroids in culture 
and we found that most human hepatocyte spheroids formed were between 50-100 
µm in size (~80%) from day 3 until Day 14 in culture (Figure 15A). However, due to 
the proliferative nature of Huh 7.5 cells, most Huh 7.5 spheroids were between 100-
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150 µm (55%) in size on day3 of culture and there was an increase in number of 
spheroids of 150-200 µm (9% to 36%) in diameter from day 3 to day 14 in culture 
 (Figure 15 B). 
 
 
Fig 15: Size distribution of spheroids A) Human hepatocytes and B) Huh 7.5 cells 
in spheroid culture over 14 days. n=30 spheroids  
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3.12.2 Characterization of spheroids using scanning electron microscopy (SEM): 
We further wanted to determine the surface morphology of the spheroid constructs 
and performed SEM analysis of the spheroids in culture over 6 weeks. Spheroid 
cultures of Huh 7.5 cells formed compacted spheroids within 3 days of culture and 
maintained their spheroid morphology over 3 weeks in culture after which they 
disaggregated (Figure 16 A). The Huh 7.5 cells do not show any special features on 
the surface of the spheroids, which could be due to the lower polarity and low levels 
of bile canaliculi expression of these cells. The human hepatocytes formed tight 
aggregates within 24 hours and packed to form tightly aggregated spheroids within 3 
days in culture. The human hepatocyte spheroids maintained their spheroid 
morphology over 6 weeks in culture and displayed distinct surface cavities on the 
spheroids, which is hypothesized to be the bile canaliculi like structures, which are 
extending from the surface to the interior of the spheroid (Figure 16 B&C). 
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Fig 16: Scanning electron microscope images of A) Huh 7.5 cells B) human       
hepatocytes and C) high magnification images of human hepatocytes 
 
3.12.3 Characterization of presence of apical and basolateral domains in 
spheroid cultured cells: 
Spheroids of both Huh 7.5 cells and human hepatocytes expressed both MRP2 and 
CD147 which are indicators of apical and basolateral domain markers.  
In Huh 7.5 cells the MRP2 protein is localized at the apical domain and form 
punctated structures, which do not extend to form tube like structures like the bile 
canaliculi in the liver. This could be because the Huh7.5 cells are not known to be 
highly polarized cells and have lower levels of MRP2 protein expressed compared to 
human hepatocytes [152]. The basolateral domain is well defined as seen by the 
staining of CD147, which is a basolateral specific marker (Figure 17 A). 
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 The human hepatocytes form well-defined apical domain, which is indicated by 
staining or MRP2 protein, which is localized in the apical domain of hepatocytes. 
This indicates the formation of hepatocyte polarity, which is important for excretion 
of bile acids. This is necessary for maintenance of high hepatocyte function and 
viability in in vitro cultures. The human hepatocytes also have well defined 
basolateral domains as indicated by the staining of CD147 (Figure 17 B). 
 
 
Fig 17: MRP2 and CD147 staining in Huh 7.5 cells (A) and Human hepatocytes 
on day 7 in culture (B). Scale 50µm 
3.12.4. Assessment of viability: 
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The Huh 7.5 cells and human hepatocytes maintained their spheroid morphology and 
have well defined basolateral and apical domains. Spheroid cultures have an inherent 
drawback, wherein cells in the core of the spheroid become hypoxic due to lack of 
nutrient and oxygen transfer when the spheroid size exceed 120-150 µm [153]. 
Further human hepatocytes also lose their viability very rapidly in culture [154]. We 
performed live dead staining of these spheroids over prolonged culture periods to 
determine whether Huh 7.5 cells and human hepatocytes maintain their viability and 
if the cells at the core of the spheroid are hypoxic. The Huh7.5 cells remained viable 
until 2 weeks of culture with no necrosis in the spheroid core but most spheroids 
disintegrated and the spheroid core became necrotic upon culture for 3 weeks. This 
could be due to the proliferative state of the Huh7.5 cells, where the spheroid size 
keeps increasing over prolonged culture leading to necrosis of the spheroid core and 
thereby leading to disassembly of the spheroid (Figure 18 A). The human hepatocytes 
cultured in the spheroid configuration maintain their viability over 6 weeks in culture 
and with very little necrosis seen in the core of the spheroid (Figure 18 B).  
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Fig 18: Cell Tracker green (green)/PI (red) staining for Huh 7.5 cells (A) and 
human hepatocytes (B). Scale 50µM 
 
 
3.12.5 Characterization of cellular phenotype: 
The Huh 7.5 cells express very low levels of hepatocyte specific function and primary 
human hepatocytes rapidly lose their differentiated functions in culture. We analyzed 
the ability of the spheroid culture system to enhance the liver specific function of 
Huh7.5 cells and maintain the liver specific function of human hepatocytes.  
The spheroid culture of Huh 7.5 cells elevated liver specific function of these cells 
over prolonged culture as indicated by the increased levels of CYP 3A4 and Albumin 
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transcript levels after 7 days of culture and transcript levels stabilized after 7 days of 
culture for all mature hepatocyte specific genes (Figure 19 B).  
Spheroid cultures of human hepatocytes preserved all important differentiation 
markers for 2 weeks in culture with minimal dedifferentiation observed compared to 
cryopreserved freshly thawed hepatocytes (Figure 19 A). 
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Fig 19: Gene expression profile of Huh 7.5 cells in spheroid configuration (A) 




 3.12.6 Expression of viral entry markers & pseudoparticle entry 
 The entry of HCV into the hepatocytes in the liver is mediated by a quartet of 
receptor, which work in unison to allow for the entry of the HCV into the host cell.  
We performed immunostaining on to determine the expression and the localization of 
these viral markers in in vitro culture. We found that both Huh 7.5 spheroids and 
human hepatocyte spheroids expressed all viral entry markers namely CD-81, claudin, 
occludin and SCARB-1. CD-81 was localized along the basolateral domain, while the 
other markers namely claudin, occludin and SCARB-1 were localized at the tight 
junction (Figure 20). 
 
 
Fig 20: Localization and expression of viral entry markers in spheroid cultures 
of Huh 7.5 cells and human hepatocytes; Scale= 50µm 
We further went on to determine if these spheroid cultures are susceptible to 
glycoprotein mediated HCV entry. We infected the cells with HCV pseudoparticle, 
which expresses the luciferase gene and is expressed in cells infected by the HCV 
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pseudoparticle. We observed that both Huh 7.5 spheroids and human hepatocytes are 
susceptible to glycoprotein-mediated entry as detected by the luciferase assay. The 
spheroid cultures also supported very high levels of HCVpp entry compared to 
conventional monolayer culture systems for both Huh 7.5 (Fig 21 A) and also primary 
human hepatocytes (Fig 21 B) thus demonstrating the advantages of the system and 
the fact that polarity is important for HCV uptake.  
 
Figure 21: Comparison of infectivity between monolayer and spheroid culture in 
A) Huh 7.5 cells and B) human hepatocytes. Data expressed as Mean+/-SEM. 
n=3, * p<0.05 
 
We also found that there is dose dependent decrease in HCVpp entry upon adding 
increasing concentrations of anti-CD81 antibody in both Huh 7.5 and Human 
hepatocyte spheroids (Figure 23). This is a proof of concept that this spheroid system 
can be a suitable system to screen for compounds inhibiting viral entry.  
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Fig 22: CD-81 dependent entry of HCVpp in spheroid cultures of Huh 7.5 (A) 
and human hepatocytes (B). Data expressed as Mean+/-SEM. n=3, *p<0.05 
 
3.12.7 HCV live viral replication: 
The system supported HCV infection, which was demonstrated using HCVpp. We  
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wanted to further determine if the spheroid cultures of the cells support replication of 
live virus in culture. We infected the cells with JFH-1 (genotype2a) strain of the virus 
and monitored replication over 8 days of culture. The primary human hepatocytes do 
not support HCV live viral replication. This is mainly due the variability of the donor 
and the non-availability of fresh human hepatocytes immediately after isolation for 
HCV replication.  The Huh 7.5 cells in both monolayer and spheroid cultures support 
replication (Figure 23) and the spheroid cultures demonstrate 8 fold higher levels of 
replication compared to monolayer cultures (Figure 24).  Thus the spheroid cultures 
show higher levels of HCV infection as well as replication compared to conventional 
monolayer cultures.  
 
 
Figure 23: JFH-1 replication in Huh 7.5 cells over 8 days in culture. Data 
expressed as Mean+/-SEM. n=3, * p<0.05 
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Figure 24: Fold change in JFH-1 copy number of the spheroids compared to 
monolayer in Huh 7.5 cells. Data expressed as Mean+/-SEM. n=3, *p<0.05 
      
3.13 Discussion:  
Here we describe an in vitro culture platform of both Huh 7.5 cells and Primary 
human hepatocytes constructed using a galactosylated cellulosic sponge, which was 
developed previously by our group [82]. The cells cultured in the cellulosic sponge 
form spheroids of uniformly sized multicellular aggregates, which is defined by the 
porosity of the scaffold. The scaffold provides the appropriate chemical cues via 
conjugation of galactose and mechanical cues via controlled mechanical stiffness of 
the scaffold for the cells. This promotes differentiation of Huh 7.5 cells to a more 
hepatocyte specific lineage and prevents the dedifferentiation of primary hepatocytes 
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over prolonged culture. This is in agreement with previously published literature that 
galactosylated substrates enhance spheroid formation [91] and spheroid cultures of 
hepatocytes enhance and maintain liver specific function of primary hepatocytes [69] 
and are transcriptionally different from traditional monolayer cultures [51].  
Both cell types in spheroid configuration are entrapped in the pores of the scaffold 
and maintain their spheroid morphology over many weeks of culture while 
maintaining their appropriate hepatocellular polarity, which is necessary to study 
various events such as chronic toxicity and progression of hepatotropic infections.  
With regards to the utility of the system to study HCV infection and replication we 
found that SCARB-1, occludin-1, claudin-1 were localized at the tight junction of 
polarized hepatocytes. This is in agreement with previous results that tight junctional 
localization of claudin and occludin are necessary for the cellular tropism of HCV and 
also entry of HCV into polarized hepatocytes [155]. The spheroid cultures also 
display similar patterns of expression of SCARB-1 and CD-81 compared to in vivo 
liver [104,	   115]. Spheroid cultures of Huh 7.5 and human hepatocytes are able to 
better organize cell adhesion and tight junctional protein complexes and express 
phenotype similar to that found in other 3D cultures which is similar to that observed 
in in vivo tissues [156].  This expression and appropriate localization of viral entry 
receptors allows for better polarization of the cells and higher infectivity of HCVpp in 
spheroid cultures over traditional monolayer cultures. Spheroid cultures provide an 
appropriate model to study HCV entry specifically to study organization, interaction 
and stoichiometry of HCV receptors and tight junctional proteins. We observed that 
the primary hepatocytes in culture were polarized and support viral entry. Previous 
reports also claim that tight junctional barriers formed in 3D constructs of human 
hepatoma cells are not inhibitory to HCV infection [157]. 
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We also observed that the Huh 7.5 cells supported HCVcc infection and replication 
and we observed increase in intracellular viral titres over 8 days in culture. The 
spheroid cultures also supported higher levels of HCV replication compared to 
traditional monolayer cultures, which could be due to the spheroid cultures exhibiting 
higher levels of phenotype and polarization allowing for greater viral entry into the 
cells. Though the spheroid cultured primary hepatocytes support higher levels of HCV 
infection compared to monolayer cultures they do not support robust replication of the 
HCV virus. This could be attributed to the presence of interferon pathways in primary 
hepatocytes that do not allow for robust replication of the HCV virus and the copy 
numbers might be too low for detection using conventional methods [158]. Newer 
more sensitive methods might help determine if the system supports replication [159].	  
With newer more effective drugs being developed to combat the disease such as 
telaprevir and sofosbuvir and the need to substitute the need for interferon treatment 
in current drug treatment regimens, in vitro systems which support HCV replication 
can be used to perform screening of combination of drugs to combat this disease and 
identify efficacies of such drugs.    
Further modification of this 3D culture system and the versatility of the system will 
allow us to culture different cell types such as HepaRG cells, iPS derived hepatocytes, 
which have been shown to support HCV and HBV infection [160,	  161].  This will 
help us overcome the current bottleneck of using primary human hepatocytes which 
are highly variable in their quality and also allow for screening compounds across 
different patient specific populations which could be useful for disease modeling and 
understanding viral lifecycle under different diseased conditions. The system also 
maintains high levels of basal metabolic function and can be used to study other 
80	  	  
endpoints such as drug metabolism, drug-drug interaction and toxicity, which are 
important parameters measured during preclinical drug development. 
 
3.14 Conclusion: 
We have developed a scalable spheroid culture system of both Huh 7.5 and Human 
hepatocytes, which can support robust infection of HCV virus in vitro. This can be 
used as a potential platform to screen drugs that inhibit HCV entry into the cells. 
Further, the Huh 7.5 cells in spheroid configuration support HCV replication more 
permissively than monolayer cultures thus allowing better sensitivity in assays where 
drug induced reduction in HCV replicons are necessary endpoints. In all we have 
developed a sensitivity scalable model to study HCV biology and to screen against 























     Chapter 4 
Co-culture of rat hepatocytes and NIH 3T3 
fibroblasts suppresses drug-induced CYP 450 











The stringent regulations and animal testing which leads to increased costs are 
compelling the pharmaceutical industry as a whole to reduce the use of animals in 
drug safety testing and to incorporate the use of in vitro liver models to detect 
problematic compounds earlier in the drug development pipeline [26]. 
Over the last two decades primary hepatocyte culture configurations such as the 
monolayer culture, sandwich culture, spheroid cultures and co-cultures in various 
forms have been developed [58, 82, 162, 163]. These configurations have been 
constructed using different matrices, scaffolds and complex micro-fabrication 
technologies [58]. The culture of hepatocytes with supporting non- parenchymal cells 
has gained increasing prominence due to its ability to support high levels of 
hepatocyte function over prolonged culture periods [58]. This has prompted the 
development of co-culture models where hepatocytes have been cultured with non-
parenchymal cells such as fibroblasts, stellate cells and kupffer cells to improve 
higher order differentiated function and to model different pathophysiology’s, such as 
angiogenesis for co-culture with endothelial cells and inflammatory responses for co-
culture with kupffer cells [164-166]. Among these, the co-culture of hepatocytes with 
NIH-3T3 a fibroblast cell line, has occupied center-place for applications such as 
developing bioreactors and bio-artificial liver devices[58, 76]. The NIH 3T3 cells do 
not express any of the liver specific drug biotransformation activities and also do not 
secrete any of the liver specific plasma protein and not susceptible to toxicity by liver 
hepatotoxicants. Therefore any functional activity will correspond to hepatocyte 
specific activity. Further these cells are easily available, express stable phenotype and 
have easy adherence to tissue culture plastic. The technical difficulties and highly 
sophisticated, expensive methods associated with the construction of these co-culture 
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models and their low throughput has restricted the adaptation of many of these models 
by the pharmaceutical industry.  The mixed co-culture of hepatocytes with NIH-3T3 
cells is easy to construct and has been shown previously to improve hepatocyte 
specific functions.  However the response of this configuration to drug induced 
responses such as drug induction, sensitivity has not been characterized.  
 Sandwich cultures of hepatocytes are easier to construct and maintain high levels of 
liver specific function with enhanced polarization [70, 167, 168]. This culture 
configuration performs well to study biliary excretory index, response to drug induced 
CYP induction and therefore is the most commonly used cellular model by the 
pharmaceutical industry to assess drug induction, interaction and transporter mediated 
uptake and efflux of drugs [169, 170]. Thus, sandwich cultured hepatocytes serve as a 
control in our studies for studying various drug- induced responses. Despite the 
robustness and utility of the sandwich culture for various drug-testing applications it 
still falls short for studying important applications such as evaluating chronic toxicity 
and response to oxidative stress related genes [26].  
Here we demonstrate the advantages of co-culture system in elevating and 
maintaining higher levels of synthetic, metabolic and excretory functions of rat 
hepatocytes compared to sandwich culture. However, the co-cultured hepatocytes 
repress drug-induced responses like CYP 450 induction and sensitivity to 






4.2 Background:  
Drug-induced liver injury (DILI) is a major health problem, which leads to liver 
failure or death. It is one of the foremost reason for withdrawal of a drug from the 
market and for labeling a drug with black box warning [171]. Due to the dire 
consequences of this problem the FDA has set up a working group comprising of 
representatives of PhRMA and AASLD and national institute of diabetes, digestive 
and kidney disease to provide insight into minimizing the risk of DILI during various 
stages of drug development and also post marketing of the drug.  
DILI is broadly classified into two categories DILI-1 and DILI-2. DILI-1 is mainly 
characterized by the higher incidence, prediction of toxicity in multiple animal models 
and increase in severity with increase in dose. One of the best examples of this form 
of toxicity is acetaminophen (paracetamol), which accounts for over 50% of acute 
liver failure in the United States [172].  The toxicity of this drug can be modeled in 
many rodent models and shows a clear dose dependent response in both human and 
animal models [173].   
DILI-2 is often referred to as idiosyncratic hepatotoxicity. In the context of drug 
toxicity it occurs in a few subsets of the population with incidences of 1 in 1000 to 1 
in 100000 patients [174] and due to its rare occurrence and not showing adverse 
effects in animals is very hard to pick up in the different phases of drug discovery. 
DILI 2 is also referred to as idiosyncratic toxicity and is defined as a toxicity, which is 
elicited by a mixture of genetic and non-genetic factors, which makes a patient 
susceptible to drug injury. Though the exact reason for this form of toxicity is not 
completely understood, there are various factors proposed for this form of injury [131, 
175, 176]. Probable mechanisms include toxicokinetic, toxicodynamic and adaptive 
reasons. Toxicokinetic mechanism includes disease states, enzyme inductions and 
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inhibitions, polymorphisms, which cause changes in the pharmacokinetics of the drug. 
The modifications of these factors have deleterious effects of increasing the 
bioavailable drug concentration, which could lead to toxicity of the liver [177]. Other 
problems arise due to the concept of polypharmacy, which is highly applicable these 
days with people being treated for multiple disorders. The use of multiple drug 
therapies may cause adverse reactions, due to their unpredictability and lack of 
information obtained from well-controlled clinical trials, which include only 
interactions between a few drug pairs.  Many disease states and infections by 
pathogens and intestinal microbes leads to an inflammation like state of the liver. 
These states increase the oxidative state of the liver and also alter the expression of  
important drug metabolizing enzymes and transporters, which again alter the 
metabolism of the drugs and alter the bioavailability of the compound leading to 
adverse events [178, 179]. It is also observed that most of the idiosyncratic toxicants 
show toxicity only after repeated drug therapy, which implicates a number of factors 
involved in the adaptive regeneration of the liver after injury to be involved in 
idiosyncratic toxicity. The adaptive responses involve pathways involved in tissue 
repair and components of the immune system, which mediate their affects by 
interactions between hepatocytes and cells and components of the immune system 
[17].  
Important liver specific factors implicated in liver toxicity/metabolism 
4.2.1 Factors eliciting toxicity: 
There are numerous factors, which control the exposure of hepatocytes to xenobiotics, 
namely a) Cytochrome P450 enzymes b) Phase II enzymes c) Transporters, which are 
all controlled by various liver enriched transcription factors. 
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4.2.2 Liver enriched nuclear factors: Liver enriched nuclear factors play a very 
important role in gene activation and they also modulate the homeostasis of drugs, 
lipids, bile acids and glucose in mammals [180]. These factors play an important role 
in coordinately modulating the expression of various key enzymes (CYP’s and phase 
II enzymes) and transporters, which could have various pathological implications 
[181]. They are also known to play an important role in drug-drug and disease-drug 
interaction. Thus the study of these factors would help us understand and reveal novel 
targets and allow us to anticipate and avoid drug-drug and drug-disease interaction. 
4.2.3 CYP450 enzymes: These enzymes play a vital role in the biotransformation of a 
drug [182]. These enzymes are heme containing monooxygenases, which are divided 
into 2 subclasses: 1) Steroidogenic and 2) Xenobiotic. The former plays an important 
role in the synthesis of steroids required for maintaining cellular differentiation. The 
latter plays a very important role in drug metabolism and disposition. These enzymes 
play an important role in detoxification of the parent drug molecule, though this is not 
always the case eg. acetaminophen. Drug metabolism is mediated by mainly by 
CYP3A (50%) and CYP2D6 (30%). CYP1A2, 2C19, 2C9 and 2E1 account for the 
rest of the 20%. However, sometimes the drug metabolism leads to formation of 
reactive metabolites, which are harmful to the cells.  Since the drug metabolism 
closely determines the toxicity profile of a drug it is of utmost importance to study the 
expression levels of these enzymes and induction of these enzymes by certain drugs, 
which might help in anticipating drug-drug interactions [FDA, 2006] and type of 




Figure 25: Proportion of drugs metabolized by CYP 450 enzymes. (Adapted with 
permission from Wrighton et al [183]) 
4.2.4 Phase II enzymes: Phase II enzymes play a important role in the phase II 
metabolism of xenobiotics, which mainly involves the conjugation of the drug to a 
specific moiety which enables its clearance into the bile or in urine. It has been 
found that many of the acyl-glucuronides and acyl-CoA are able to transacylate 
proteins and GSH and form thio-ester, ester and amide bond adducts [30]. These 
factors are also known to cause an observed adverse reaction.  
4.2.5 Transporters: It has been known for a long time that only lipophilic 
molecules can pass through the plasma membrane by passive diffusion. Hydrophilic 
molecules can pass through the membrane only by means of proteins called 
transporters. It is now known that a large number of drugs, their metabolites and bile 
acids exit and enter the cells through transporters. It is known that the liver plays a 
very important role in the metabolism and disposition of drugs. The various features 
of drug metabolism of the liver by the phase I and the phase II enzyme systems have 
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been studied over the past 2 decades [15], but little emphasis has been given to the 
study of transporters in the hepatobiliary disposition of drugs. The hepatocytes due 
to their unique position and architecture contain a wide variety of transporters which 
are localized in the basolateral and the apical domains of the hepatocytes, which 
facilitate the transport and the disposition of polar compounds as well as a few 
lipophilic molecules [184]. Thus these proteins might play a very important role in 
the disposition of the drug and the exposure of the drug to the hepatocytes. The 
basolateral transporters are uni or bi directional and play an important role in the 
transport of the drugs and metabolites from the hepatocytes to the sinusoidal blood 
and vice versa [185]. The apical transporters are responsible for the biliary excretion 
of the drugs [185].  
 
 
Figure 26: Schematic description of sinusoidal and basolateral transporters. 
(Adapted with permission from Sandy Pang et al [186]) 
The factors described above are known to work in synchrony and are known to 
contribute to toxicity elicited by drugs by various mechanisms as discussed below. 
 
4.3 General mechanism of toxicity and liver injury: 
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The response of liver cells to various drugs or foreign substances involves several 
pathways and leads to various adaptive cellular responses. Though some external 
stimuli are recognized by various cellular receptors, most drugs due to their 
hydrophobic nature enter the cell unhindered and unrecognized and lead to a variety 
of drug responses. These responses include enhanced rates of biotransformation, 
changes in drug transport, cellular stress and regenerative responses [187].  One of the 
best examples of drug-induced responses is the induction of Cytochrome P450 
enzymes, which play a role in phase I biotransformation.  Nuclear orphan receptors, 
specific to the liver, which are activated by ligands, are recognized to play a role in 
ligand/drug recognition and adaptive responses like activation of CYP 450 system and 
transporters [187].  The human and rat comprises of dimeric orphan receptors, steroid 
receptors, RXR heterodimers and monomeric receptors [188]. Here we will discuss 
the role of major orphan receptors inducing the major CYP 450 pathways namely:  
AhR, PXR, FXR and CAR. 
4.3.1 Aryl hydrocarbon receptor: 
 The Aryl Hydrocarbon Receptor (AhR) is a major transcription factor that is 
responsible for the induction of CYP1A1, 1A2 and CYP1B1 [189, 190]. This receptor 
is also known to be responsible for the regulation of some phase II enzymes GST and 
UGT [191]. AhR in its inactive form occurs as a complex in the cytoplasm with hsp90 
and co-chaperon protein p23 [192].  Ligand binding to this receptor leads to 
disassociation of the complex and translocation of the AhR to the nucleus where it 
binds to AhR nuclear translocator (AhRNT) also known as HIF-1β [193]. This 
heterodimer binds to XRE  (Xenobiotic Response Element), which in turn activates 
the CYP 450 enzymes and other enzymes leading to biotransformation. AhR is 
responsible for mediating carcinogenicity, teratogenic effects of its ligands [194-196]. 
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AhR also plays an important role in cytokine signaling and inflammation [197]. 
Interaction with nuclear transcription factors is also relevant for AhR mediated 
toxicity. AhR is known to interact with NF-kB, which controls a variety of 
physiological and pathological responses.  In addition AhR crosstalk with retinoic 
acid receptor (RAR), vitamin D receptor (VDR) and peroxisome proliferator activated 
receptors (PPAR’s) has been reported [198]. 
 
 
Figure 27:  Schematic of AhR activation. (Adapted with permission from 
Androutsopoulos et   al[199]) 
 
4.3.2 The pregnane X receptor: 
The pregnane X receptor is also known as the steroid X receptor or Xenobiotic 
receptor. It belongs to the NR1 family of receptors, which also includes Vitamin D 
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receptor (VDR) and constitutive androstane receptor (CAR) [200]. The PXR binds to 
CYP response elements and is responsible for the activation and induction of CYP 
3A4 and CYP 3A7 [201, 202]. There is also evidence suggesting the role of PXR in 
the regulation of CYP 2C8, 2C9 and 3A11 [203, 204]. The downstream effectors of 
PXR pathways are known to play an important role in metabolism of xenobiotics and 
bile acids. Therefore PXR is implicated in the progression of cholestasis and drug 
induced hepatomegaly due to its effects on bile acid metabolism and transport [204].   
Several substances are known to activate PXR; important examples are steroid 
hormones and their metabolites, statins, anti cancer drugs and anti diabetic drugs 
[205, 206]. One of the most potent inhibitors of PXR is hyperforin an active 
component of St John’s Wort’s [207].  
PXR is present as a heterodimer with RXR and is present only in the nucleus. [208].  
Most notably PXR is activated by pregnonelone carbonitrile (PCN), which activates 
CYP3A. Expression of PXR is stimulated by the glucocorticoid receptor [204].  
PXR also interacts with HNF4alpha a receptor involved in the embryonic 
development and differentiation of the liver [209]. It has also been observed that bile 
acids activate PXR receptors. Therefore it is now believed that induction of PXR 
induces the CYP 450 enzymes, which in turn metabolize the harmful bile acids 
generated [204].  
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Figure 28: Schematic of PXR activation by ligand. (Adapted with permission 
from Handschin et al [210]) 
 
4.3.3 The constitutive androstane receptor: 
The CAR is located in the cytoplasm and is found in the Nucleus as a heterodimer 
with RXR upon activation. This receptor controls the expression of the CYP (2C, 2B 
and 3A) isoforms and phase II (UGT1A1) of biotransformation and transporters for 
bile acids and xenobiotics [203].  
CAR is mainly activated by phenobarbital and phenobarbital like compounds and 
endogenous bile metabolites [211]. The transcriptional regulation of CAR is 
controlled by the glucocorticoid receptors [203]. Its is also known that release of 
proinflammatory cytokines such as Il-6 or IL-1β repress the expression of 
glucocorticoid receptor which in turn repressed CAR activity[203].  
CAR has also been implicated in the toxicity caused by many liver toxicants like 
acetaminophen (APAP) proven by the lack of toxicity in CAR null mice [212]   
4.3.4 Farsenoid X receptor (FXR): 
93	  	  
Farsenoid receptor is belongs to a super family of RXR heterodimers. The FXR along 
with LXR is an essential component of the cholesterol homeostasis to which bile 
acids are important ligands.  This receptor is present in liver, kidney and intestine. 
This receptor has largely been implicated in the development and progression of 
cholestasis [213].  
4.3.5 Peroxisome proliferator – activated receptor (PPAR’s): 
PPAR’s are named based on their ability to activate peroxisome proliferators after 
xenobiotic stimuli. There are 3 isoforms of PPAR’s namely PPAR alpha, gamma and 
delta. PPAR alpha is the most widely present PPAR in the liver. 
The PPAR’s possess anti-inflammatory capacity, which they elicit by production of 
anti-inflammatory molecules and suppression of pro-inflammatory cytokines [214].  
xenobiotics, fatty acids and eicosanoids are ligands for this receptor [215] . These 
form heterodimers with RXR and bind to peroxisome proliferator response elements 
[216]. There are also suggestions of cross talk between PPAR alpha and CAR [202]. 
This receptor is mainly known as site of action of fibrates and leads to unfortunate 
drug-drug interactions when co-administered with statins [216]. Peroxisome 
proliferators have been shown to cause local toxicity due to the reduction of 
mitochondrial uptake [217]. Thus has been shown to have protective effects when 
taken with drugs, which are known to cause oxidative cellular stress. PPARα also is 
known to suppress the activation of NF-kB . In general PPARα have been shown to 
play a major role in xenobiotic response.  Furthermore PPAR has also been implicated 
in the formation of hepatocarcinogenesis [218]. 
 
4.4 Biotransformation, CYP induction and how it leads to toxicity. 
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The liver plays an important role in metabolism of xenobiotics.  Inhibition and/or 
induction of these metabolizing enzymes have great effects on the effects of drugs and 
also their toxicity.  
The biotransformation is mainly divided into three major phases: 
4.4.1 Phase I:  
Phase I reactions are mainly carried out by hydrolases, and oxidoreductases such as 
CYP 450 dependent monooxygenases and cyclooxygenases.  Most phase 1 reactions 
increase the polarity of the xenobiotic compound by introducing new functional 
groups on the drug molecule.  
4.4.2 Phase II:  
Phase II reactions mainly are glucuronidation, sulfation and mainly entail the 
conjugation of drug or its metabolite to endogenous hydrophilic molecules resulting 
in increased polarity and water solubility to help achieve proper elimination. 
4.4.3 Phase III:  
Phase III reactions describes transport processes which are carried out by drug 
transporting proteins like Organic anion transporting proteins (Oatps’s), Organic 
Cationic proteins (Oct’s), Multidrug resistant proteins (MDR’s) and Multi drug 
associated proteins (MRP) and Bile Salt excretory proteins (BSEP) which mediate the 
influx and efflux of drugs and their metabolites from the blood and into the bile [219].   
There are important ways toxicity arises from interaction at metabolizing enzyme 
levels: 1) Enzyme induction and 2) Enzyme inhibition 
Enzyme induction has been implicated in drug induced liver toxicity and also leads to 
unfavorable drug-drug interactions. Enzyme induction leads to generation of bioactive 
metabolites by certain detoxifying enzymes mainly CYP 450’s. This is mainly seen in 
the toxicity elicited by drugs such as APAP and flutamide, which form the toxic, 
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intermediates namely NAPQI and 4-hydroxy flutamide upon metabolism that are 
toxic to the liver.  These toxic metabolites form toxic adducts with conjugating 
enzymes or mitochondrial phospholipids, which causes progression of mitochondrial 
damage [220]. These enzyme inductions also lead to undue generation of reactive 
oxygen species formed during biotransformation. This leads to undue generation of 
superoxide ions as seen in metabolism of certain drugs like paraquat and doxorubicin 
[221]. Drug-drug interactions during the phase I metabolism stage leads to severe 
clinical consequences affecting not only the liver but also other vital organs. The 
toxicity of these interactions is mainly attributed to the increasing concentration of the 
drugs or its activated metabolite, however sometimes it leads to increased clearance of 
the substrate of the metabolizing enzyme.  
With regards to the CYP monooxygenase reactions, different xenobiotic inducers can 
be distinguished on the cytochrome P450 they induce. They are phenobarbital type 
inducing CYP 2B, 3A and 2C’s. Dexamethasone and PCN type (CYP3A, 2C, 2B), 
ethanol and isoniazid type (CYP2E1), clofibrate type (CYP 4A1) and polyaromatic 
type (CYP 1A1, 1A2, 1B1).  
 
4.5 APAP metabolism as an example for toxic metabolite mediated  
      hepatotoxicity: 
Production of toxic metabolites upon metabolism of the parent compound is an 
important way in which toxicity is elicited by a number of compounds. The best 
example for this form of toxicity is toxicity elicited by acetaminophen (APAP). APAP 
is an analgesic and is a major cause of acute hepatotoxicity upon overdosing and leads 
to centrilobular necrosis [222].  The reactive metabolite of APAP metabolism by 
CYP1A2, 2E1 and 3A2 is N-acetyl-p-benzoquinone imine (NAPQI) [223]. This 
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metabolite affects the cellular metabolism and is also known to affect gene 
expression, protein expression and activity. NAPQI is known to inhibit many 
processes involving cellular metabolism, which are physiologically relevant. It is 
known to affect the rate-limiting step of glutathione synthesis, which is responsible 
for detoxification and clearance of oxidative radicals [224]. Further NAPQI is an 
inducer of CYP2E1, which produced ROS such as superoxide radicals, and H2O2 
[225]. Accordingly it is believed that the hepatotoxicity of NAPQI is at least in part 
due to production of oxidative stress resulting from futile cycling of CYP 450 leading 
to reduction of molecular oxygen [226]. ROS is believed to be toxic to APAP treated 
hepatocytes, since both APAP and NAPQI are detoxified by conjugation to GSH, 
resulting in depletion of GSH. Presence of bioactive metabolite NAPQI is also 
associated with the manifestation of disease like reduction in GSH levels, protein 
adduct formation and ROS formation [227]. These features mediate enhanced 
activation of genes encoding for antioxidant proteins and phase II enzymes by Nrf-2 
and Nfκ-B pathways [228]. Despite these findings there is a lot of missing links in 
elucidating the exact mechanism of APAP toxicity especially the interplay between 
different cell types and their effect on hepatotoxicity.  
 
4.6 Cytokines and role in liver diseases: 
Cytokines are extracellular proteins that are responsible for the regulation of the 
innate and immunological inflammatory reactions. They are involved in various 
processes like cell differentiation, growth, repair processes and for maintenance of 
homeostasis [229]. With regards to the liver, cytokines and other molecules act in 
concert and contribute to liver physiology and pathophysiology.  It is clear that liver 
regeneration requires coordinated signals to process normally and also normal 
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functioning of liver requires release of certain factors and cytokines. IFN-alpha is 
used to treat viral hepatitis [230]. STAT-1 activated by IFN alpha and gamma plays a 
role in antiviral defense mechanism of the liver but also suppressed hepatocyte 
polarity. STAT2 contributes to the antiviral property of interferons. Abnormal 
cytokine metabolism is a major feature of diseases like ALD. Inhibition of IL-10 and 
TNF-α leads to reduction or suppression of ALD. 
Profibrinogenic cytokines like IL-6 and TGF-β1 determine the extent of fibrosis 
[231]. Thus understanding the role of cytokines in regulating the functions of liver 
cells should help us develop treatment for liver disease and also understand how 
cytokines modulate liver function and liver toxicity.  
The description of the mechanisms of toxicity and the factors playing an important 
role in eliciting and regulating various drug-induced responses allows us to delineate 
and study markers and proteins important in understanding the differences between 
the cellular models and also key factors responsible for the differentials observed.  
 
4.7 Materials and Methods: 
   
4.7.1 NIH 3T3 culture: 
 
NIH 3T3 cells were maintained in tissue culture polystyrene in DMEM (High 
glucose) supplemented with 10% FBS and passaged at 80% confluence. Cells were 
sourced from ATCC. 
4.7.2 Rat hepatocyte isolation and culture: 
 
Primary hepatocytes were harvested from male wistar rats weighing 250–300 g by a 
two-step in situ collagenase perfusion method. 200–300 million cells were isolated 
from each rat with viability >90% as determined by the trypan blue exclusion assay.  
For collagen sandwich cultures freshly isolated rat hepatocytes (0.3 million cells per 
well) were seeding in 500 µL William’s E culture media in a 24-well plate coated 
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with 1.5 mg/mL collagen (Vitrogen Angiotech Biomaterials Corp). Another layer of 
collagen was overlaid 24 hours after initial cell seeding. For co-cultures, freshly 
isolated rat hepatocytes and NIH 3T3 cells were mixed in a ratio of 1:1 and seeded on 
24 well plates coated with 1.5mg/mL collagen in 500 µL of Williams E media.  
Sandwich cultures and co-cultures were maintained in William’s E media, 
supplemented with 1 mg/mL bovine serum albumin (BSA), 0.5 mg/mL of insulin, 
50 nM dexamethasone, 50 ng/mL linoleic acid, 100 U/mL penicillin and 100 µg/mL 
streptomycin. For cultures with TGF-β1, TGF-β1 was added to the media at a final 
concentration of 0.2 ng/mL and the culture medium was changed daily. 
4.7.3 Hepatocyte synthetic function: 
 
On days 1, 3, 5 and 7 cell culture media samples were collected for measuring cell 
function. Albumin secreted in the culture medium was measured using a rat albumin 
ELISA quantitation kit (Bethyl Laboratories Inc., Montgomery, Texas, USA). Urea 
production in the culture medium was measured using a Urea Nitrogen Kit (Stanbio 
Laboratory, Boerne, Texas, USA). The data was normalized to the total hepatocyte 
number in culture.  
4.7.4 CYP induction assay: 
 
3 days after culture the cells were treated with 40 µM β-naphthoflavone (βNF) 
inducer of Cyp1a2, 1 mM phenobarbital (PB) inducer of Cyp2b1/2 and 50 µM 
pregnenolone-16 α-carbonitrile (PCN) inducer of Cyp3a2. Dimethyl sulfoxide 
(DMSO) was used to prepare stock solutions and the final concentration in the culture 
medium for cell treatment did not exceed 0.1%. The cultures were treated with the 
inducers for 48 hours with replenishment every 24 hours. For CYP mRNA analysis, 
cells were lysed at the end of treatment period and total RNA was isolated using 
RNeasy mini kit (Qiagen). For activity analysis, CYP specific probe substrates 
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(Cyp1a2: 200 µM phenacetin; Cyp2b1/2: 200 µM bupropion; Cyp3a2: 5 µM 
midazolam) were diluted in Krebs-Henseleit buffer (KHB) and added to the cells for 2 
hours, after the 48-hour inducer treatment. The metabolites were collected and stored 
at −80 °C until measurement by liquid chromatography-mass spectrometry (LC/MS).  
4.7.5 RT-PCR: 
 
Total RNA was isolated using RNeasy mini kit and 1000 ng of RNA was converted to 
cDNA using high capacity RNA-cDNA kit (Applied biosystems). 10ng of cDNA was 
used to perform RT-PCR using SYBR green method (ROCHE). Gene expression was 
performed using rat specific primers and normalized to β-actin. Relative expression 
was calculated by delta-delta Ct method.   
Genes Sequence 
1a2 F: CACGGCTTTCTGACAGACCC 
R: CCAAGCCGAAGAGCATCACC 
2b1/2 F: TCTCACAGGCACCATCCCT 
R: GTGGGTCATGGAGAGCTG 
3a2 F: TGGGACCCGCACACATGGACT 
R: TCCGTGATGGCAAACAGAGGCA 
AhR F: ACTACACGCCAGACCAGCTT 
R: ATCATGCCAGGAAACCAG 
CAR F: GGAGGACCAGATCTCCCTTC 
R: GACCGCATCTTCCATCTGT 
PXR F: GGTCTTCAAATCTGCCGTGT 
R: GTTTCATGGCCCTTCTGAAA 
MRP3 F: ATCATGCCAGGAAACCAG 
R:  ATCATGCCAGGAAACCAG 
NTCP F: CATTATCTTCCGGTGCTATGA 
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R: GTTTCTGAGCATCGGGATT 
OATP1 F: CTTAAAGCCAACGCAAGACC 
R: AGAGATACCCAAGGGCACAA 
MRP2 F: CGCGAGGAGAGCATTAT 
R: GGCAAGGTAGAATTTGGTTAT 
                                 Table 6: List of rat hepatocyte specific primers 
 
4.7.6 LC/MS measurement of CYP specific metabolites: 
 
300 µL of sample containing metabolites were added with 50 µL of 100 ng/mL 
internal standards and dried using a concentrator (Eppendorf 5301, Hamburg, 
Germany) under vacuum. The dried residues were reconstituted using 50 µL methanol 
containing 0.1% formic acid and centrifuged at 1 × 104 rpm for 10 min. The 
supernatants were then used for measurement by LC/MS system (LC: 1100 series, 
Agilent, Singapore; MS: LCQ Deca XP Max, Finnigan, Singapore) with 
100 × 3.0 mm onyx-monolithic C18 column (Phenomenex, CA, USA). The mobile 
phase consisted of solvent A (0.1% formic acid in water) and solvent B (0.1% formic 
acid in methanol) with a flow rate of 0.8 mL/min. The elution scheme for the 
measurement of acetaminophen and 1′-OH–midazolam involved solvent B which was 
gradually increased from 6% to 90% over 6 min. For OH-bupropion measurement, 
solvent B was gradually increased from 10 to 90% over 6 min. The MS parameter 
settings were as follows: spray voltage 5 kV; sheath gas flow rate: 80; auxiliary gas 
flow rate: 20; capillary temperature: 350 °C; tube lens: 45 V; and capillary voltage: 
30 V. 
4.7.7 Hepatocyte excretory functions: 
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For visualization of fluorescein excretion, 15 µg/mL fluorescein diacetate (FDA) 
(Molecular Probes, Eugene, Oregon, USA) diluted in culture medium was incubated 
with the cells in various culture configurations at 37 °C for 45 min. The cells were 
then rinsed, before viewing under a confocal microscope (Zeiss 510) using a 
60 × water lens. 
4.7.8 TGF-β1 pull-down: 
 
1µg of TGF-β1 antibody was added to conditioned media and incubated at 4 °C 
overnight. To this 50 µL of protein A/G was added and mixed for 2 h at 4 °C. The 
protein A/G beads were then removed by centrifugation at 14,000RPM for 10 minutes 
after which supernatant was collected. 
4.7.9 EROD assay: 
The 7- ethoxyresorufin-O-deethylation (EROD) assay measures the de-ethylation 
activity of cytochrome P450 (CYP) 1A-associated monooxygenase enzymes, was 
initiated by incubating the cells with culture medium containing 10 µM 7- 
ethoxyresorufin at 37 °C for 1h. The amount of resorufin converted by the enzymes 
was calculated by measuring the resorufin fluorescence in the incubation medium at 
530nm excitation/585nm. (Tecan Safire, Switzerland) 
4.7.10 Measurement of drug sensitivity: 
After 2 days of cell seeding, the sandwich culture and the co-culture configurations 
were exposed to APAP at a final concentration of 20mM and 40mM. DMSO was 
used to prepare the stock solution and the final concentration of DMSO for drug 
treatment did not exceed 0.1%. The cell viability was measured using MTS assay 





4.8.1 Characterization of synthetic and metabolic functions of sandwich culture 
and co-culture: 
 
Key representative differentiated functions namely Albumin, urea synthesis were 
characterized between sandwich cultured and co-cultured hepatocytes. The co-culture 
of hepatocytes and NIH 3T3 fibroblasts demonstrated significantly higher levels of 
urea secretion over 7 days in culture. The most dramatic increase in urea secretion 
was observed on day 5 and day 7 in culture with a 2 fold and 8 fold increase over 
collagen sandwich respectively (Fig 29).   
 
Figure 29: Characterization of rate of urea production in sandwich culture and co-
culture of hepatocytes with NIH 3T3 fibroblasts. Data expressed as Mean+/- SD, n=3, 
* p<0.05 
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Albumin levels in both the sandwich culture system and co-culture system were 
between 15-60 (µg/million cells/day) over 7 days in culture. Albumin secretion in 
collagen sandwich system gradually decreased from Day 1 of culture until day 5 of 
culture with the level of albumin secretion stabilizing from day 5 to day 7. Co-culture 
system showed an increased level of albumin secretion on day 3 of culture following 
which there was a sharp drop and stabilization of albumin secretion from day 5 to day 
7 with levels similar to collagen sandwich system (Fig 30).  
 
 
Figure 30: Characterization of rate of albumin production in sandwich culture and 
co-culture of hepatocytes with NIH-3T3 fibroblasts. Data expressed as Mean+/- SD, 
n=3, * p<0.05 
Metabolic capacity of the hepatocytes in the different culture systems was probed by 
their ability to form metabolites from various probe substrates specific to CYP 1a2, 
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2b1/2 and 3a2. The co-culture models maintain higher levels of metabolic activity 
over sandwich culture over 7 days of culture with the most dramatic fold increase 
observed on day 5 (5 fold for 1a2, 2.5 fold for 2b1/2 and 3 for 3a2) and day 7 (3 fold 
for 1a2, 3.2 fold for 2b1/2 and 5 fold for 3a2) of culture for all the important CYP 450 
enzymes (Fig 31).   
 
Figure 31. Fold change in CYP activity of various CYP 450 enzymes of co-
culture normalized to sandwich culture. Data expressed as Mean +/- SD. n=3 
The increase in the synthetic function and metabolic functions of co-culture over 
sandwich culture is in agreement with previously published findings showing 
enhancement in synthetic and metabolic functions in co-culture systems. The 
observed increase in the co-culture system could be due to heterotypic interactions 
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between hepatocytes and fibroblasts and important soluble factors secreted into the 
media.  
 
4.8.2 Comparing drug sensitivity and drug induction between co-culture and  
sandwich culture: 
 
The improvement of synthetic and metabolic activity of hepatocytes prompted us to 
investigate the application of these systems for drug testing applications importantly; 
acute sensitivity to drugs and drug induction applications required by FDA for 
approval of most drugs.  
We tested the sensitivity of the sandwich system and co-culture for toxicity to 
Acetaminophen a paradigm hepatotoxicant. At 20mM we found the sandwich culture 
to be more sensitive to the compound; 60% cell death as against 33% in co-culture. 
However at 40mM concentration of the drug both sandwich culture and co-culture 
system showed similar levels of toxicity (Fig 32).  Sandwich culture therefore could 
be a more sensitive model for drug screening to determine acute toxicity of drugs.  
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Figure 32: Comparison of sensitivity of sandwich culture and co-culture to paradigm  
hepatotoxicant APAP at 20 and 40mM.  Data expressed as Mean+/- SD. n=3; * p<0.05 
 
Further, we evaluated both systems for their ability to study drug induction which 
leads to drug interactions and also hepatotoxicity and is an important parameter 
required by the FDA to be tested for most drug candidates. We compared the 
sandwich and co-culture systems for their ability to induce CYP1a2, 2b1/2 and CYP 
3a2. To study this phenomenon we induced the hepatocytes and co-culture with 
prototypical drug inducers BNF for 1a2, PCN for 3a2 and PB for 2b1/2. We found 
that at the mRNA level the sandwich-cultured hepatocytes showed significantly 
higher induction (Fold change compared to untreated controls) compared to co-
cultured hepatocytes for important CYP 450 enzymes (6 fold for 1a2, 5.5 fold for 
2b1/2 and 2.7 fold for 3a2 on a log2 scale)  (Fig 33). However, at the CYP activity 
levels, analyzed by various metabolites formed from probe substrates; the sandwich 
culture shows similar levels of induction compared to the co-culture (Fig 35). The 
discrepancy in the induction at mRNA and activity levels could be explained by the 
discrepancy in the correlation between mRNA and activity measurement CYP 
induction or because of higher basal levels of co-culture, where the fold change in 
induction is getting saturated [232] and/or regulation happening only at the 
transcriptional level.  
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Figure 33: Comparison of drug-induced responses between sandwich and co-culture 
at transcript and activity level upon exposure to paradigm CYP 450 inducers. Data 
expressed as Mean +/- SD. n=3; * p<0.05 
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These results are contradictory to literature published, which shows higher levels of 
CYP induction in co-culture compared to sandwich cultured hepatocytes. This could 
be because of less than optimal controls in previous studies where sandwich cultured 
hepatocytes were cultured in the presence of serum, which is known to affect the 
phenotype of hepatocytes undesirably and also affect drug induction.  
 
4.8.3 TGF-β1 is an important regulator of hepatocyte function: 
  
 
We have previously shown that TGFβ1 is an important regulator of hepatocyte 
specific function in co-culture [84]. We wanted to determine if reconstitution of 
TGFβ1 in sandwich culture elevates synthetic functions and metabolic activity of 
hepatocytes in sandwich culture.   
We evaluated urea secretion in the sandwich culture in the presence and absence of 
0.2ng/mL of TGFβ1 over 5 days in culture. We found that TGFβ1 significantly 
improved urea secretion by 2 fold on day 3 and day 5 in culture over control, however 
we did observe decrease in urea synthesis over time and urea synthesis levels were 
similar after 5 days in culture between control and TGFβ1 treated samples (Fig 34) 
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Figure 34: Effect of TGF β1 on rate of urea synthesis in sandwich cultured rat 
hepatocytes.  Data expressed as Mean +/- SD. n=3; * p<0.05 
 
 
 TGFβ1 also up-regulated various important hepatocyte specific genes namely various 
CYP 450 genes, orphan receptors and various drug transporters. Most genes were up-
regulated 2-4 fold over control (Fig 35). Reconstitution of TGFβ1 improved EROD 




Figure 35: Effect of TGF β1 on transcript levels of important liver specific markers 





4.8.4 TGFβ1 is an important factor repressing CYP induction in co-culture:  
 
Since TGFβ1 was shown to be important factor up-regulating important factors like 
urea secretion and improved gene expression of various CYP450 enzymes and 
transporters in culture we wanted to further investigate if TGFβ1 is an important 
factor responsible for the observed decrease in CYP induction in co-culture.  
We first depleted the conditioned media of TGFβ1 by pull-down assay using TGFβ1 
specific antibody. We then performed CYP 450 induction in sandwich-cultured 
hepatocytes in conditioned media and media depleted of TGFβ1. We found that 
hepatocytes cultured in the media depleted of TGFβ1 showed recovery of CYP 450 
induction (2.2 fold for 1a2, 2 fold for 2b1/2 and 1.2 fold for 3a2 on a log2 scale) 
compared to induced hepatocytes in conditioned media for all important CYP 450 
enzymes (Fig 36). 
 
Figure 36: Fold change in transcript levels of CYP450 enzymes induced in 
conditioned media and media depleted of TGF β1. Data expressed as Mean+/-SD. 
n=3; * p<0.05 
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To further prove that TGFβ1 is an important factor repressing CYP induction, we 
reconstituted sandwich cultured hepatocytes with 0.2ng/mL of TGFβ1 and performed CYP 
induction with and without TGFβ1. We found that hepatocytes induced with prototypical 
CYP 450 inducers in the presence of TGFβ1 exhibit repressed CYP induction (9 fold for 
1a2, 2 fold for 2b1/2 and 2.8 fold for 3a2) compared to cells induced in absence of TGFβ1 
(Fig 37).  
 
Figure 37: Fold change in transcript levels of CYP 450 enzymes upon induction in 
absence (control) and presence of TGF β1. Data expressed as Mean+/-SD. n=3; * 
p<0.05 
We further went on to determine if the regulation of the CYP induction in the 
presence of TGFβ1 is controlled at the transcriptional level and by nuclear orphan 
receptors. We found that when hepatocytes are induced in the presence of TGFβ1 we 
observed a repression in the induction of important nuclear orphan receptors namely 
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AhR (regulates induction of CYP 1a2) when induced with BNF and PXR (which 
regulates induction of 3a2) when induced with PCN. However, we do not see a 
repression of CAR in the presence of TGFβ1 and PCN (Fig 38). This could be 
because PCN does not activate the CYP 3a2 enzymes by the CAR pathway but acts 
via the PXR mediated pathway.   
 
 
Figure 38: Fold change in the transcript levels of transcription factors induced in the 
presence and absence of TGF β1 normalized to uninduced controls. Data expressed as 
Mean+/-SD. n=3 
These studies prove that TGFβ1 is directly responsible for repressed CYP induction in 
co-cultured model of hepatocytes and NIH-3T3 fibroblasts, which is mediated by 
repressing nuclear orphan receptors.  
4.8.5 Co-culture and TGFβ1 enhance hepatocellular excretory function:  
 
We performed fluorescein di acetate assay to determine the polarity of the hepatocytes 
cultured in sandwich culture, co-culture and sandwich cultured hepatocytes cultured 
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in the presence of 0.2 ng/mL TGFβ1.  We observed faster establishment of 
hepatocellular polarity in 48 hours in cell cultured in the presence of TGFβ1 and in 
co-cultured hepatocytes and fibroblasts compared to cells cultured in sandwich 











 Various applications of liver tissue engineering require hepatocytes to express high 
levels of synthetic and metabolic functions in vitro [233]. Specialized applications 
like hepatotoxicity testing require hepatocytes to maintain high levels of metabolic 
function, higher sensitivity to drug induction and sensitivity to drug induced toxicity 
[90, 162].  Hepatocytes in sandwich culture maintain their polarity and high levels of 
differentiated function and are currently the gold standard for drug testing 
applications in the pharmaceutical industry [83].  Some of the limitations of sandwich 
culture model such as non responsiveness to oxidative stress pathways, non formation 
of the complete repertoire of metabolites have prompted the development of other 
engineered models such as co-culture of hepatocytes and fibroblasts for maintaining 
enhanced function and metabolic activity [26, 234].  However, a true utility of both 
these systems for drug testing applications has not been evaluated.  Here we analyze 
the salient features of both these systems and their applicability to various fields of 
drug testing.  
 
The co-culture of hepatocytes and fibroblasts was developed to enhance and maintain 
differentiated function of hepatocytes [235]. The co-cultured hepatocytes with NIH 
3T3 fibroblasts enhanced urea synthesis and metabolic functions significantly over 
sandwich culture over 1 week of culture.  
This provided a proof of concept that the current co-culture model of hepatocytes and 
NIH 3T3 cells enhance and maintain hepatocyte specific function. The elevation in 
the liver specific phenotype could be due to two causes namely the heterotypic 
interactions between the hepatocytes and the fibroblasts [57, 58] and also the release 
of various soluble factors in the co-culture, which enhance liver specific phenotype 
[84, 236].   
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Comparing the drug-induced effects on the co-cultured hepatocytes and sandwich-
cultured hepatocytes, co-culture repressed drug-induced responses compared to 
sandwich cultured hepatocytes. This is in contrast with literature, which shows greater 
induced responses and sensitivity in co-culture compared to sandwich cultured 
hepatocytes [58, 237]. This discrepancy could be explained by the different choice of 
media used to culture cells in our system where both sandwich culture and co-culture 
configurations are cultured in the absence of serum.  Serum is known to negatively 
affect cellular function, viability and metabolic activity in sandwich culture of 
hepatocytes [238].  
We have previously shown that TGFβ1 at low concentrations to be a key regulator of 
hepatocyte function in hepatocyte NIH 3T3 co-culture [84]. This factor has been 
implicated in elevating cellular function, binding to important drug inducing genes 
[84, 239, 240] and also leading to apoptosis in various epithelial cells [241] . 
Reconstitution of sandwich culture with TGFβ1 leads to improved gene expression of 
various hepatocyte specific differentiated genes and also elevates levels of urea up to 
3 days in culture.  The drop in functional levels of sandwich cultured cells in the 
presence of TGFβ1 on day 5 of culture could be due to the lack of heterotypic 
interactions, desensitization of the cells to TGFβ1 or its short half life. These 
drawbacks can be overcome by using controlled release of TGFβ1 as shown 
previously [242]. Since TGFβ1 was shown to play a major role in determining the 
characteristics of co-cultured hepatocytes we hypothesized the important role of 
TGFβ1 in repressing drug-induced responses in co-culture. Depletion of TGFβ1 from 
conditioned media helped in the recovery of drug induced CYP induction compared to 
cells induced in conditioned media. Further, reconstitution of TGFβ1 in sandwich-
cultured hepatocytes repressed drug induced responses compared to hepatocytes 
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induced in the absence of TGFβ1. These repressed responses are controlled by 
interaction of ligands and drug response elements [243]. Here we also demonstrate the 
transcriptional repression of nuclear orphan receptors, which regulate drug induction 
in hepatocytes. 
Various applications of liver tissue engineering have different requirements with 
respect to the specificity of phenotype expressed and response required. Careful 
consideration has to be made before selecting a specific model for the required 
application. Hepatotoxicity testing of drugs is a field heavily reliant upon in vitro liver 
models. Sandwich cultured hepatocytes are a gold standard and co-cultures are 
gaining prominence in this arena to address specific toxicity applications [26]. Co-
cultures are complex systems to control and the mixed co-culture is the easiest system 
adaptable by the industry. However, despite the mixed co-culture of hepatocytes and 
NIH 3T3 cells elevating metabolic and synthetic functions they repress drug induced 
CYP responses, which is mediated by TGFβ1 thus making it an unsuitable model for 





We have evaluated the salient features of the sandwich culture system and the 
Hepatocyte: NIH 3T3 co-culture for their ability to support liver specific synthetic 
function, metabolism and drug-induced responses. Co-cultures elevate and maintain 
synthetic and metabolic functions of hepatocytes. However, the co-cultures repress 
drug induced CYP responses compared to sandwich cultured hepatocytes. This 
repression in drug induced responses and elevation of synthetic liver functions in 















 Chapter 5 













5.1 Liver tissue engineering 
 
Liver tissue engineering is adopting a purpose-driven and bottom-up approach to 
integrate biomaterials, engineered liver cells, and microtissue constructs tailored for 
specific in vitro and in vivo applications [26]. The successful integration requires 
precision toolbox components that can be adapted or custom-engineered to satisfy a 
set of pre-defined design parameters which highly depend on our understanding of the 
quantitative relationship between the biomaterials, cells, constructs and final 
application requirements. Rapid developments in quantitative profiling (with various 
–omics technology) of cellular responses to biomaterials and microenvironments, 
combinatorial chemistry and automated high-throughput screening platforms to 
synthesize and screen biomaterial libraries allow for systems-level measurements of 
the toolbox parameters that can be linked in computational models [244, 245]. Some 
have already employed computational models to quantitatively predict cellular and 
molecular level behaviors, outcomes of in vitro constructs and to gain insight from in 
vivo conditions [246]. These predictive models are capable of simulating certain 
outcomes by predicting in vivo behaviors such as drug disposition based on in silico 
and in vitro modeling of processes such as the hepatocyte drug transport [247]. As 
more such models are established to quantitatively link the design parameters of 
biomaterials, cells and micro-tissue constructs to final application requirements, we 
can envision the coming era of designer biomaterials with optimal performance for 






5.2 Hepatotoxicity testing and predictivity: 
 
Great strides have been made in the understanding of the components that contribute 
to hepatotoxicity and a large number of in vitro models have been developed.   
We have demonstrated the advantages and the limitations of the most widely used in 
vitro models with regards to only a few important aspects of drug testing namely drug 
metabolism and drug induction.  However this phenomenon accounts for only some 
of the hepatotoxic responses that occurs and majority of the problematic compounds 
are still not picked up earlier in the drug discovery phases. There are very few current 
models that pick up idiosyncratic toxicity and even some of the models, which work 
today have very low predictivity of around 30% [248] and mainly work only for 
drugs, that lead to toxicity during inflammatory state or in conditions which cause 
oxidative stress [249]. Though acute toxicity at very high drug concentrations which 
are non physiological have been picked up pretty well in in vitro cultures 
(determination of IC50), establishing the mechanisms of toxicity and toxicity 
occurring upon chronic dosing at physiologically relevant has not been as successful 
and is the current need of the pharmaceutical industry to reduce attrition of 
compounds during drug development [250].  
This higher predictivity can be achieved by using techniques like toxicogenomics that 
will surpass the current techniques in terms of speed and sensitivity. In response to 
insults, the physiological changes, which are observed are at a later stage and gene 
expression and protein changes occur a lot faster and the reconstruction of these 
responses can be give an idea of the related mechanism of toxicity [251].  Early 
toxicogenomic studies have shown their ability to distinguish two mechanistically 
unrelated toxicants based on cluster type analysis [252]. McMillian and coworkers 
have performed detailed characterization of drug induced oxidative stress in rat liver 
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via a methodology of toxicogenomics [253]. They first established transcriptional 
gene signature of macrophage activators using paradigm compounds, which served as 
training sets. They then identified macrophage activator like compounds. Using a 
similar strategy they constructed transcriptional gene signatures for Peroxisome 
proliferators. They also constructed gene signatures for oxidative stressor/reactive 
metabolites hepatotoxicants and similarly they identified similar signatures for this 
scenario too. This approach is very elegant, in the sense that it allows for the 
classification of different toxicants and also possible mechanism of toxicity in drug 
induced oxidative stress. However the finding of the whole approach was that most 
OS/RM genes are regulated by Nrf-2, which binds to the antioxidant response element 
(ARE) and further activates many of the detoxifying phase II genes [254].  They 
further also identified that compounds classified under macrophage activators could 
activate STAT3 and NF-κB while peroxisome proliferators activate PPAR-alpha. In 
summary the toxicogenomic approach gives us a very powerful tool to classify 
compounds, understand mechanism of toxicity and also molecular and cellular 
networks underlying these events.  
These techniques and gene signatures involved could be extrapolated to human liver 
and hepatocytes and could also provide interesting signatures on toxicity mechanisms. 
In vitro models could be further developed and improved and many of these drugs, 
which cause oxidative stress/reactive metabolite responses, could be analyzed for 
their gene signature in in vitro models, which exhibit high fidelity.  This could further 
the whole field of mechanistic toxicity testing and also make in vitro models as the 
models of choice for routine mechanistic studies due to their ease of use and ability to 
work with human samples.  
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5.3 Hepatitis C infections and drug development: 
Most of our current information on the understanding the life cycle of the Hepatitis C 
virus has been obtained from genomic and subgenomic replicons of the virus in 
hepatoma cells [86]. However, the identification of JFH- 1 a full length HCV virus of 
genotype 2a and its replication in hepatoma cells without any adaptive mutations has 
provided us a great insight into the life cycle of this virus and into host virus 
interaction [87], though this has not led to significant increase in drugs released for all 
strains of the virus causing this disease. One of the main reasons for this is JFH-1 is a 
genotype 2 virus, while most of the western world is affected by genotype 1 of the 
virus; the strain not susceptible to the current line of treatment [255] though a few 
drugs have been released which work against all genotypes of the virus.  The current 
hepatoma cell lines that are used namely the Huh7 and the Huh 7.5 cells only allow 
for replication of genotype 2 of the virus and also have mutations in RIG-1 pathways 
and do not allow for the accurate study of innate immune response of the liver to the 
viral infection [256]. This indirectly affects drug development and possible targets for 
which drugs can be designed.  
The spheroid cultures of both Huh 7.5 cells and human hepatocytes, which are 
capable of high levels of viral infection and Huh 7.5 cells support higher levels of 
viral replication compared to monolayer and traditional culture and can be maintained 
in culture for longer periods of time. This opens up other avenues for studying in the 
disease such as progression of hepatitis C infections and molecular signatures 
associated with it in vitro and cell-cell transmission of the virus. Spheroid cultures 
exhibit accurate localization and expression of viral entry markers similar to that 
observed in vivo. This helps us study more accurately the exact process of viral entry 
as against that elucidated in 2D cultures.  The 3D human hepatocytes supporting high 
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levels of infection and persistent replication also allow for the study of the accurate 
drug responses that are activated by various strains of the virus.  
However the difficulty in obtaining high quality human hepatocytes from donors 
makes it very difficult to use in vitro systems with primary human hepatocytes for 
routine drug screening. We envision a future where we will obtain human hepatocytes 
from sources such as humanized mice where fresh human hepatocytes can be obtained 
from mice, which have been implanted with liver cells of human donors supporting 
HCV infection. Other alternatives can be iPS-derived hepatocytes, which can support 
HCV replication. This will allow us to screen for differences in metabolic capacities 
of different donors and also identify the differences in drug responses among different 
patient lines. This will help us estimate the efficacy of the drug among different ethnic 
groups/different patients well before the clinical trials.  
The 3D spheroid system, which allows for hepatitis C replication holds great promise 
for the future and the salient features of this system allow it to be scalable amenable to 
screening in 96 well plate format allowing for high throughput and routine screening 
of anti-viral drugs and also a system for basic biological research to understand host-
virus responses. The system can also be extrapolated for the study of HBV and 
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